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Abstract 
Background: Chronic diseases of lifestyle are typically diseases of long duration and slow 
progression and are the major cause of morbidity and mortality globally 
1
. In 2008, 57 million people 
died worldwide of which 33 million deaths were due to chronic diseases 
2
. The burden of chronic 
disease in low and middle income countries is increasing, yet the capacity for prevention and control 
thereof is inadequate 
2
. It has been suggested that more than 50 % of global deaths can be prevented 
by combining cost effective national and international efforts as well as individual action to target 
management of well established risk factors including increasing physical activity, improvement of 
nutrition, decrease tobacco and alcohol use and implementation of strategies to address adverse 
psychosocial stress 
3
. 
The Chronic Disease Risk Reduction and Reversal program (CDRRRP) is a lifestyle intervention 
programme based at the Clinical Sport and Exercise Medicine Practice that is located at the Sports 
Science Institute of South Africa. The programme caters for patients with established chronic disease 
including cardiovascular disease, diabetes mellitus, chronic respiratory disease, cancer, fibromyalgia, 
chronic renal disorders, myopathies, and joint degeneration. The CDRRRP involves a systematic 
assessment and supervised lifestyle intervention programme (including an exercise regime), focusing 
on increasing the functional capacity and psychological well-being of these patients. The aims of the 
programme is to limit the negative physiological and psychological effects of chronic disease, to 
reduce the risk of further pathologies and events, to stabilize or reverse further progressions of 
chronic disease, to improve functional and exercise capacity and overall to enhance the patients well 
being. While many studies have examined the impact of diet or exercise programs on risk, few have 
examined programs that are multidisciplinary or holistic in nature. In our study, we wanted to 
determine the patients who were referred and fully funded compared to those who proactively referred 
and funded themselves through the CDRRRP.  It is assumed that all patients will show improvements 
in the outcome variables and decrease their risk factor levels. However, when comparing the medical 
insurer referred and funded group of patients to the self funded group of patients, it is hypothesised 
that the self funded patients will show a greater readiness to change and subsequent adaptation 
because they have a greater vested interest in their compliance and participation in the CDRRRP due 
to the fact that they financially funded themselves through the programme.  
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Objective:   The main aims of this dissertation were 1) to review the existing literature focussing on 
the prevalence, associated risk factors, management and treatment interventions of chronic disease, 
and 2)  to compare rehabilitation outcomes between a pilot group of patients referred and funded to 
the CDRRRP by their medical insurer, namely Fedhealth (FH) versus a self funded and referred 
group (SF) of patients with chronic disease, to determine if any differences exist in their outcomes 
achieved after completing the 12 week programme, and 3) to evaluate the effect of a chronic disease 
rehabilitation programme on outcomes after 12 weeks (36 sessions) for chronic disease patients. 
Methods:  This study analyzed if differences existed in outcomes measured between a medical 
insurer referred and funded group (FH) of chronic disease patients versus a self initiated and funded 
group (SF) of chronic disease patients after 12 weeks (36 sessions) of a chronic disease rehabilitation 
programme (CDRRRP). The study also examined the overall effect of the CDRRRP on patients with 
chronic disease. The main outcomes measured were weight, body mass index, body fat percentage, 
waist circumference, hip circumference, waist-to-hip ratio, resting heart rate, resting blood pressure, 
total cholesterol, LDL, HDL and triglyceride concentration as well as, functional capacity measured as 
the 6 min walk test. 
Results:  Two hundred and nine patients with chronic disease (176 males [86 %]; 33 females [14 %]) 
were admitted to the CDRRRP during the observation period. One hundred and seventy nine 
completed the programme. Paired t-tests were used to assess for changes from baseline to 12 weeks 
(36 sessions) and completion of the CDRRRP. Between the two groups of patients, namely the funder 
funded and referred; Fedhealth (FH) group and self funded (SF) group, no significant changes in 
variables were found. However, there were significant improvements found in the total group of 
patients from admission (T1) until completion of the 36 session programme. (T2) These differences 
were noted in the following parameters; total cholesterol concentration (p: 0.0015), LDL concentration 
(p:0.0001), resting heart rate (p:0.0001), resting systolic blood pressure (p< 0.0001), resting diastolic 
blood pressure (p< 0.0001), body fat percentage (p< 0.0001), sum of skin folds (p< 0.0001), waist 
circumference (p< 0.0001), hip circumference (p< 0.0001), waist-to-hip ratio (p< 0.0001), flexibility (p< 
0.0001), six minute walk test distance (p< 0.0001), and maximum heart rate (p< 0.0001) . Thus, the 
programme had the overall effect of favourably altering metabolic, cardiovascular and anthropometric 
variables as well as improving functional capacity. Conclusion:  This multidisciplinary lifestyle 
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intervention program was effective in reducing the chronic disease risk factors among patients with 
chronic disease. There was no difference in outcomes measured between the two groups, suggestive 
that there are no differences in adaptation, adherence or compliance amongst patients who are both 
referred and funded compared with patients who initiate and fund themselves through a chronic 
disease rehabilitation programme. Future studies should examine whether the changes seen after 12 
weeks are increased or sustained. 
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CHAPTER 1 
Introduction and scope of the thesis 
Chronic diseases of lifestyle are a major global burden in health care. Currently, these diseases 
contribute to more than 60 % of all deaths worldwide 
1
. More than 80 % of these deaths occur in low-
income and middle-income countries 
4
. It is projected that the number of deaths due to cardiovascular 
disease will rise from 17 million in 2008 to 25 million in 2030 
5
. 
There are four main categories chronic non-communicable diseases, namely cardiovascular disease, 
diabetes, cancer and chronic respiratory diseases. The majority of the chronic disease of lifestyle 
share similar risk factors including poor diet, tobacco use, lack of regular exercise and chronic 
psychosocial stress, and the major risk factors linked to these diseases are high blood pressure, 
tobacco and alcohol use, high serum cholesterol, physical inactivity and obesity 
1
.  
Previous interventions for chronic disease designed for individual diseases including cardiac, 
pulmonary, stroke or orthopaedic rehabilitation, have provided favourable results. However, evidence 
has shown that, within South Africa, more than 50 % of medically insured members have significant 
co-morbidities namely, more than one simultaneous chronic disease 
46,105
. This has created the need 
for a shift towards developing more patient-centred interventions taking into consideration that 
patients frequently suffer from a multitude of chronic conditions including musculoskeletal conditions. 
 
It is well known that rehabilitation is an integral component of the care of patients with chronic disease 
6
. Multi-disciplinary rehabilitation programmes reduce the impact of chronic disease on health 
services, communities and the individual. Patients who have access to multi-component rehabilitation 
services have an improved quality of life through increased functional capacity and a sense of control 
of their life through improved understanding of their disease and its management. The key 
components of the optimal chronic disease rehabilitation should include exercise, education, a dietary 
and nutrition component, psychosocial support and strategies to modify other risk factors. 
 
Therefore the aim of this thesis was to investigate the effects of a chronic disease rehabilitation 
programme on the health and outcomes in chronic disease patients. An analysis was also conducted 
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14 
to determine if a difference in rehabilitation outcomes existed between two groups from different 
referral and funding strategies. 
    
 
 
 
 
 
 
 
 
 
 
••• 
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CHAPTER 2 
Rehabilitation outcomes of patients with chronic disease to a lifestyle 
intervention programme: A review of the prevalence of chronic disease and 
lifestyle interventions 
 
2.1 Introduction 
Chronic diseases of lifestyle are typically diseases of long duration and slow progression and are the 
major cause of morbidity and mortality globally 
1
. The World Health Organization (WHO) has identified 
non-communicable disease as a leading threat to human health and development. There are four 
main categories chronic disease that constitute this group, namely cardiovascular disease, diabetes, 
cancer and chronic respiratory diseases. The majority of the chronic diseases of lifestyle share similar 
risk factors including poor diet, tobacco use, lack of regular exercise and chronic psychosocial stress. 
The major risk factors linked to these diseases are high blood pressure, tobacco and alcohol use, 
high cholesterol, physical inactivity and obesity.  
 
2.2 The burden of the chronic diseases of lifestyle 
Of the 57 million people deaths globally in 2008, 33 million were due to chronic diseases 
2
. More than 
80% of these deaths occurred in low-income and middle-income countries 
4
. The burden of chronic 
disease in low and middle income countries is on the rise, yet the capacity for prevention and control 
thereof is inadequate 
1;2;7
.  It has been estimated that 32 million deaths from chronic disease could be 
averted in 10 years in countries that have a high burden of these diseases if global efforts were 
further widespread and more cost effective interventions endorsed and implemented 
8
. It is projected 
that the number of deaths due to cardiovascular disease will rise from 17 million in 2008 to 25 million 
in 2030. Cancer deaths are also expected to increase from 7.6 million to 12 million. The total number 
of deaths due to chronic disease is expected to reach 55 million by 2030 
7;9
. There has been strong 
evidence presented by the UN General Assembly demonstrating the link between poverty, lack of 
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education and other social determinants to chronic diseases and their risk factors. This has created 
an unfavourable cycle whereby chronic disease and the associated risk factors worsen poverty which 
causes a further increase in chronic disease 
10
. 
In developing countries, 48 % of all chronic disease related deaths occur in people under the age of 
70 years. These figures are projected to increase from 10.8 million in 2010 to 15.4 million in 2050. In 
comparison, deaths from infectious disease are expected to decline by 2 % per year over the next 
forty years 
11
. 
This prevalence of premature deaths has major adverse social, economic, and health outcomes for 
these poorer, low income countries 
7;12
. Their capacity to effectively cope with a shrinking workforce 
and sick population is challenged and the healthcare systems and resources are placed under 
enormous strain.  
There is also a negative effect on the individual, who struggles to be productive and healthy. This 
ultimately affects their earning capacity and potential, impacting on their investment and education 
opportunities, socioeconomic status as well as their families 
11
. On a national level, chronic disease 
reduces life expectancy which adversely affects economic productivity ultimately depleting the 
workforce 
13
. However, these diseases have a negative effect across all age groups.  Indeed, nearly a 
quarter of all chronic disease related deaths are amongst those aged 60 years old and constitute 
substantial challenge to the economies, society, families and the sustainability of health care systems 
internationally. In fact, if no further action is taken to improve the global chronic disease profile, the 
WHO has estimated by 2020, 73 % more healthy years will be lost to chronic disease 
12;14
. Different 
methods exist to quantify the burden of chronic disease. The mostly used method is the approach that 
measures the global burden of chronic disease in terms of Disability Adjusted Life Years (DALYs). 
This is a combination of Years of Life Lost (YLL) through premature death and Years Lived with 
Disability (YLD). Hence, DALY is considered of as one lost year of healthy life 
15
. 
Global deaths can be prevented by combining cost effective national and international efforts as well 
as individual action to target the management of well established risk factors by increasing physical 
activity, improving nutrition, decreasing tobacco and alcohol use and implementing strategies to 
address adverse psychosocial stress 
3;16
.  As stated in the UN General report (2011) the knowledge 
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17 
and technology already exists to tackle the onset and effects of chronic disease and it is up to global 
health efforts to effectively implement the proven and affordable measures and efforts 
10
. 
Indeed, some countries have established strategies and guidelines to address chronic disease and 
their associated risk factors, through changes to healthcare infrastructure, new and better funding 
systems and improved monitoring systems and policy responses 
1
. An example of this can be seen in 
the success of the North Karelia Project in Finland 
6
. This project was launched 25 years ago to help 
reduce the exceptionally high coronary heart disease mortality rates in the area. With the assistance 
of local and national authorities as well as WHO, the project was designed and implemented to carry 
out interventions through community organizations and involve health services, schools, NGO’s, local 
media and the food industry. The results of this project are evident in the reduction in nearly all risk 
factors associated with chronic disease, resulting in a 73 % decrease in cardiovascular mortality rates 
in 1995 
6
. 
Unfortunately, these efforts are not repeated, especially in developing countries. A more organized 
and collaborated movement is needed especially with changes to policies and initiated community-
based efforts. Only for the second time in its history, the UN General Assembly held a high level 
meeting on Non-Communicable Diseases in September 2011 (the first meeting held was for 
HIV/AIDS in 2001) to create a greater awareness and implement a call to action towards tackling this 
global crisis 
10
. The President of the General Assembly pledged to examine better options to improve 
prevention and stated “there had been too much focus on too few illnesses.” The ban of smoking in 
restaurants and public areas in New York City was used to illustrate the effective use of public policy 
and strict campaign implementation in reducing both adult and teenage smoking rates 
10
.  Key issues 
that are pivotal to moving forward with chronic disease prevention and awareness are approaches 
that include cost effective interventions aimed at addressing risk factors, stronger surveillance and 
monitoring and improved access to basic health care needs. This requires investments both in time 
and finances but can lead to quick gains in counteracting the effects of chronic disease 
6;10
. 
South Africa is both diverse and unique as seen in its history, economy and population 
17
. In South 
Africa, 33 % of all deaths are due to chronic diseases 
18
. Cardiovascular disease accounted for 11 %; 
cancer 7 %;chronic respiratory disease and diabetes were 3 % respectively and 4 % to other chronic 
diseases and injuries 
18
. 
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The chronic disease trends within South Africa are also affected by the HIV/AIDS epidemic and 
socioeconomic factors such as poverty, urbanization and industrialization 
14;19
. Furthermore, the 
impact of these chronic diseases is compounded by the high injury rate due to violence, high crimes 
and traffic accidents. This complex burden of diseases places an excessive demand on the health 
services in South Africa, stretching it beyond its available resources. However, there has been very 
little recognition given to the severity of the burden of chronic diseases of lifestyle in South Africa 
20
. 
In 2002, The South African Demographic Health Survey (SADHS) was conducted among the general 
South African population, and showed that 55 % and 29 % of South African women and men 
respectively, were overweight, nearly half of the men and women were physically inactive and 42% of 
men and 11% of women were smokers 
20
. 
Nearly 60 % of all South African adults have at least one major reversible risk factor 
19;21
. In 2003, the 
World Health survey released data indicating that data were released from a World Health survey 
displaying the following factors attributable to deaths in 2000, tobacco use accounted for 8-9 %, 
excessive body weight 7 %, alcohol use 7.1 %, physical inactivity 3.3 %; high blood pressure 9 %;  
high cholesterol 4.6 % and diabetes 4.3 % 
22
. 
 
2.3 Chronic non-communicable diseases and risk factors. 
2.3.1 The four main chronic non-communicable diseases. 
The four main chronic non-communicable diseases include: 
Cardiovascular Disease (CVD). 
Cardiovascular disease includes both the heart and blood vessels. More than 82 % of global mortality 
is caused by ischemic heart disease, stroke, hypertension and congestive heart failure. Within the 
past ten years, CVD has become the highest cause of death worldwide 
1
.  
Diabetes. 
Diabetes is a metabolic disorder characterized by disordered regulation of blood glucose 
concentrations. Type 1 diabetes accounts for 5–10 % of patients with diabetes and is characterised 
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19 
by pancreatic β-cell destruction usually leading to insulin deficiency 
23
. Type 2 diabetes accounts for 
over 90 % of all diabetes and is characterized by insulin resistance and a relative insulin deficiency 
24
.Type 2 diabetes has important lifestyle associated risk factors that include obesity, physical 
inactivity, poor nutritional choices and psychosocial factors 
23
.  Diabetes is a major risk factor for 
cardiovascular disease, renal disease and blindness leading to increased morbidity and mortality 
1
.  
Cancer. 
Cancer is characterized by a rapid growth and division of abnormal cells within a part of the body. 
These cells have the destructive ability to outlive, metastasize or invade and spread to other parts of 
the body. There are over 100 different types of cancer as well as different associated risk factors. 
Cancer is the second highest cause of death worldwide 
1
. In South Africa, lung cancer is the leading 
cause of cancer deaths accounting for 17 %, oesophageal cancer follows with 13 %, cervical cancer 8 
%, breast cancer 8 % and liver cancer 6 % 
25
.  
Chronic respiratory disease. 
Asthma, Chronic Obstructive Pulmonary Diseases (COPD), respiratory allergies, pulmonary 
hypertension are the common forms of chronic respiratory diseases 
1;26
. The most common of these is 
COPD, which includes chronic bronchitis and emphysema, and is characterized by the obstruction of 
airflow; it is progressive and not always reversible 
26-28
. Chronic respiratory diseases account for 7 % 
of all deaths worldwide. 
1;26
. 
2.3.2 The four main risk factors for chronic non-communicable diseases. 
Despite the growing public awareness of chronic diseases of lifestyle, there is generally a poor 
understanding on how the associated risk factors contribute towards the development and 
progression of the disease. Many patients are uneducated regarding the effect that their lifestyle 
behaviour choices have on their health and the risk this places on the development and progression 
of chronic disease. This lack of knowledge and education makes the treatment and management of 
these disease challenging. Besides poor knowledge of the disease states, the development of many 
chronic diseases, can largely be attributed to poor lifestyle choices, which includes poor dietary 
factors, physical inactivity, tobacco and alcohol use and high psychosocial stress 
1
.  
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
 
 
20 
Physical inactivity. 
The WHO recently reported strong evidence that physical inactivity contributed towards 80 % of heart 
disease, stroke, type 2 diabetes and 40 % of cancers 
3
. Guthold et al
29
 produced data from a survey 
of 51 countries which showed that 47.6 % of women and 44.7 % of men were physically inactive 
29;30
. 
The 2002 South African Youth Risk Behaviour Survey showed a similar pattern among young people. 
43 % of females and 30.5 % of males were physically inactive 
30;31
. 
Physical activity delays the onset of illness and disease and acts directly on the cardiovascular 
system causing favourable changes in metabolism and body composition and weight. 
1
. The health 
benefits of physical activity increase with an increase in physical activity frequency and intensity. The 
evidence has shown that the effects of exercise are, short lived. Maintaining these positive changes 
on health requires a long term commitment to regular consistent exercise 
32
.  It can be concluded that 
being physically inactive would be detrimental to one’s health especially with respect to the 
development of chronic disease. In today’s society people are finding their lifestyles have been 
adapted and modified to ‘move less’. In fact, a great portion of the populations’ occupation requires 
them to be sedentary. Worksite health promotion programmes have increased over the past decade 
to tackle this health issue by implementing physical activity initiatives during working hours, such as 
lunchtime walking groups and worksite exercise programmes and facilities. Subsequently, the WHO 
developed the Global Strategy on Diet, Physical Activity and Health (DPAS), to promote health 
awareness by creating environments that allow sustainable healthy behaviours by individuals and 
communities at national and global levels 
33
. Together these actions will lead to a reduction in chronic 
disease development and deaths 
3
. 
Poor diet. 
Lifestyle choices with respect to diet are important in both primary and secondary prevention of 
chronic disease 
22;34
. The change in nutrition and dietary intake due to globalization and urbanization 
has resulted in foods being more processed and high in sugars, unhealthy fats and refined 
carbohydrates. This has resulted in obesity related health consequences, which are on the increase, 
especially in developing countries 
18
. Obesity is currently the fifth leading risk factor for global deaths. 
More than 2.8 million people die globally each year as a result of obesity. Furthermore the burden of, 
diabetes (44 %), ischemic heart disease (23 %) and cancers (7-41 %) is attributable to obesity 
5
. 
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The patterns in consumer consumption have been strongly influenced by the relative price changes 
for fresh fruits and vegetables, sugars and sweets, and carbonated drinks. A study highlighted by the 
WHO report 2008 showed the substantial increase in the prices of fresh fruit and vegetables between 
1978-2009 and the decrease in prices for sugars, sweets and carbonated drinks. These trends 
together with the financial recession, has forced people to make food choices based on price and not 
health 
35
. 
South African diets have also been demonstrated to be high in these foods. Learners frequently 
consume fast foods (38.8 %), cakes and biscuits (47.4 %), cool drinks and sweets (52 %) at least four 
days a week. The data also showed that urban and rural areas show similar consumer patterns 
6;30
. 
Tobacco use. 
Tobacco use is one of the most modifiable risk factors and preventable causes of death in the world. 
The World Health Organization (WHO) has attributed four million deaths a year to tobacco. It is 
estimated that by 2030 smoking will kill one in six people globally 
30
. In South Africa, approximately 31 
% of men aged 15 years and older smoke daily, compared to only 8 % of women 
24
.  
Individuals who smoke expose themselves to nicotine, tobacco, tar, carbon monoxide and many other 
harmful chemicals. Smoking increases the risk of at least 50 medical conditions. Interventions such as 
counselling and pharmacological therapies can be implemented to assist with smoking cessation 
22
. 
Psychosocial stress. 
Stress is associated with destructive behaviour patterns and choices and has adverse effects on the 
body systems. It impacts negatively on hormonal responses, and causes abnormalities in metabolic 
response, inflammatory response, glucose and insulin control 
22
. Anger, depression and anxiety all 
contribute towards increased risk of cardiovascular disease 
22
.  Stress is also linked to non 
compliance with medications and poor lifestyle choices such as dietary choices, smoking, drug 
addiction and sedentary behaviour 
36
.  Stress is a modifiable risk factor and there are tools and 
techniques such as learning to breathe correctly, meditation and regular exercise, which can be 
implemented to help reduce the affects of stress 
22
. 
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2.4 Primary, secondary and tertiary prevention of chronic disease. 
Maintaining a healthy lifestyle and engaging in regular physical activity contribute towards primary and 
secondary prevention of chronic disease 
8
. Yet, people with a chronic disease especially 
cardiovascular disease tend to be overweight and physically inactive 
37
. Although the benefits of 
attending a lifestyle rehabilitation or intervention programme have been well documented, many 
people with chronic disease still choose to exercise insufficiently and maintain a poor weight and 
lifestyle. People with chronic disease who do not attend a formal lifestyle intervention programme are 
thought to have higher risk profiles because of their poor risk factor knowledge and poor lifestyle 
behaviours 
36
. Strategies for disease prevention may be divided into primary, secondary, and tertiary 
according to the presence or absence of disease and its severity. The term ‘prevention’ is used with 
reference to efforts in promoting, protecting and sustaining good health 
34
. Recently, the success of 
reducing chronic disease has been mostly due to secondary and tertiary prevention treatments, yet 
there needs to be a greater emphasis on primary prevention and better investment and endorsement 
of medical insurers into tertiary prevention to achieve greater reductions in chronic disease mortality 
34
. All tiers of prevention contain similar principles including the use of preventative medications, 
lifestyle interventions, psychosocial interventions, diet and nutritional interventions, physical activity. 
These factors are all targeted by educational modules, behaviour interventions and policies by 
government to improve health of all individuals 
34
. Developing a holistic healthcare system that 
incorporates all levels of prevention, will enable cost effective and achievable improvements in health 
across all populations.
34
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Figure 1. The prevention pyramid consisting of primary, secondary and tertiary levels of 
prevention 
Primary prevention addresses the prevention the development of risk factors in healthy individuals. 
Primary prevention interventions focus on maintaining a healthy lifestyle, limiting the incidence of 
disease and associated risk factors and encourage activities that promote good health 
34
.  Examples 
include exercising five or more times a week, optimal dietary intake, non-use of alcohol and tobacco, 
and stress management. It is important this level of prevention starts at government, public policy 
development, town planning and within the communities. 
In the United States, it is estimated that an investment of $10 per person annually in community 
based programs targeting physical inactivity, poor diet and smoking could save more than $16 billion 
in medical costs each year over 5 years 
38
. 
Secondary prevention occurs after the identification of risk factors and/or disease. The goals are to 
reduce the progression of disease through early detection and early treatment 
34
. Examples of 
interventions include the Discovery Vitality “healthy living’ initiative, the Healthy Weight programme at 
the Sport Science Institute of South Africa and the Greater Green Triangle (GGT) Diabetes 
Prevention project in Australia 
39
.  At this level of prevention, the patient is typically asymptomatic but 
requires the individual to be actively involved in monitoring and managing their associated risk factors. 
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For example, regular monitoring  of cholesterol levels, blood pressure, cessation of smoking, weight 
reduction, diabetes management, psychosocial stress management and physical activity education 
and training 
40
.   
Tertiary prevention is practiced after an event or established disease has occurred or has been 
diagnosed 
41
. The goal of tertiary prevention is to improve functional capacity, minimise the effect of 
the disease, and prevention further complications and events through aggressive management of risk 
factors and physical and psychological rehabilitation 
34
.  Interventions within this category are directed 
at individuals with established disease who are considered high risk. Medically supervised 
programmes such as The Chronic Disease Risk Reversal and Reduction Programme at the Sport 
Science Institute of South Africa are designed specifically to meet the needs of these individuals. The 
concept of high risk is used to describe individuals with three or more risk factors present as well as 
established disease according to the ACSM 
42
. Although only 5-10 % of the total population fall within 
this tier of prevention, however, it is estimated that the cost of medically treating these individuals 
contributes to 80 % of total medical insurers costs 
43
. 
Thus, there is a need for interventions on all tiers 
8;18
. Yet, in South Africa, the promotion of healthy 
lifestyles, prevention of chronic disease through early diagnosis and cost effective management of the 
risk factors seems not to be a high priority in relation to other infectious diseases 
41
.  The model for 
patient care, on which most developed and developing countries base their health-care facilities, are 
based predominantly on acute patient care and do not incorporate the patient in an active way to 
ensure compliance with long-term medical treatment or the necessary lifestyle modifications 
44;45
.  
Effective management of the chronic diseases of lifestyle requires that the patient becomes an active 
participant in their own care and treatment.  
 
2.5 Disease specific versus patient centred approach to chronic disease 
rehabilitation. 
 
Disease centred interventions were introduced in South Africa in the 1970’s with the advent of 
Cardiac Rehabilitation. In the 1990’s, the medical aid schemes started a small but active interest in 
the prevention, diagnosis and treatment of specific diseases. In 2005, the Risk Equalisation Fund 
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study (completed in South Africa) 
45,46
, identified that more than half of medical aid members had one 
or more chronic disease and that some patients were being treated for up to eleven chronic conditions 
simultaneously 
46;47
. 
The first disease centred programmes introduced were for diabetes and asthma because they were 
seen as tractable and measurable in terms of the effectiveness of interventions. Although cardiac 
conditions were more prevalent conditions cardiac programmes were seen less frequently. Jollife et al 
(2004) conducted a review on cardiac rehabilitation programmes, and found there was a reduction in 
total mortality in patients who underwent a cardiac programme by 26-31 % 
48
. Similarly, benefits were 
also seen in COPD patients who engaged in a pulmonary rehabilitation programme. There were no 
improvements in pulmonary function but there were significant improvements in functional and 
maximal exercise performance, peripheral and respiratory muscle strength, and quality of life. 
However, there was a 31 % dropout rate of patients by the sixth month and 36 % by the eighteenth 
month 
49
. This is suggestive that these patients who took part in a disease centred intervention did not 
adopt the necessary lifestyle and behaviour changes that would have been implemented more 
effectively in a multi-component chronic disease programme. 
 
In Canada, the First Step programme 
50
 and study evaluated the effects of daily exercise, specifically 
walking, on glucose control in type 2 diabetics. The results showed an improvement in walking 
behaviour and biometric measurements at 16 weeks. However, the high rates of relapse by week 24 
was also indicative that a stronger, more holistic intervention was needed amongst patients who 
present with more than one risk factor for chronic disease 
50
.  
The TOHMS study 
51
 conducted in the United States, investigated the normal pharmacological 
interventions for the treatment of stage 1 hypertension in conjunction with a lifestyle intervention in 
comparison to a control group who received a placebo as well as a lifestyle intervention. Results 
showed continued improvements in weight up to 4 years after the intervention, physical activity 
increased by 86 % and improved blood pressure and blood lipid profile changes were also recorded. 
These results also support the role for lifestyle interventions and showed that the implementation of 
such programmes can be achieved in a clinical setting 
51
. 
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The Extensive Lifestyle Management Intervention (ELMI) was evaluated in Canada by Lear et al 
(2003)
51
. The Extensive Lifestyle Management Intervention (ELMI) was a one-year intervention 
designed at chronic disease risk factor control and rehabilitation. Patients with ischemic heart disease 
were followed after completion of a cardiac rehabilitation programme and were randomized to either 
ELMI or usual patient care. ELMI included exercise sessions, telephone follow-ups and risk factor and 
lifestyle counselling. The study concluded that a one-year multi-factorial post-cardiac rehabilitation 
programme intervention resulted in a modest increase in beneficial effects compared to usual care 
52
. 
This again, provides further evidence for the need of a patient centred lifestyle intervention instead of 
a disease centred approach when treating patients with chronic disease. 
 
A further study in Germany compared multidisciplinary rehabilitation versus usual care for patients 
with chronic low back pain showed that patients responded better to the multidisciplinary intervention. 
It was also mentioned that specialized back rehabilitation centres were rare and not readily available 
for all patients 
53
. 
 
However, although the health improvements are evident from these disease centred programmes, 
they are not ideal for patients with multiple diseases. They are not sufficiently comprehensive and 
only focus on the disease at hand and do not take into consideration the patient and their existing co-
morbidities. Access to these programmes is also limited as well as access to resources in terms of 
educated and qualified staff, facilities and availability to the larger populations who are in need of such 
treatment and interventions. 
 
Today, some of the leading medical aid schemes or medical insurers have moved towards 
programmes addressing high-cost individuals who have multiple conditions, a more patient centred 
approach. The Old Mutual Healthcare Surveys in 2003 showed that 59 % of medical schemes had 
disease management programmes in place, and indeed have increased from 38 % in 1999. Thus, the 
focus is slowly shifting to the person rather than the disease 
46;47
. However, better developed patient-
centred approaches still need to be implemented for environments that lack appropriate resources, 
such as the primary health care services in the public sector of the country 
19
. 
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2.6 Interventions to address the chronic diseases of lifestyle. 
“Lifestyle” is a complex concept within the framework of medicine. It refers to a way of living of 
individuals, families and societies and includes coping mechanisms within their physical, psychosocial 
and economic environments 
17
.  Lifestyle also reflects an individual’s attitude and values as well as 
how they view their health. It is therefore the individual that plays an active role in determining their 
health through daily choices in dietary habits, physical activity, the use of tobacco, alcohol and other 
risky behaviours 
54
.  
Lifestyle interventions should be used in conjunction with conventional medicine to lower the impact of 
chronic disease on health services through reduced re-hospitalisation and decrease reliance on other 
community services and treatment such as medications 
55
. 
Such interventions include nutrition management, physical activity, stress management, sleep 
management, and smoking cessation. This would involve educating and coaching patients to improve 
personal lifestyle choices, anxiety and chronic psychosocial stress management as well as risky 
behaviours and habits 
17
. 
Goble and Worcester (1999) gave a definition of chronic disease rehabilitation that includes concepts 
from the WHO, the United States Public Health Service and the European Society of Cardiology. 
They describe rehabilitation as: ‘… the coordinated sum of interventions required to ensure the best 
physical, psychological and social conditions so that patients with chronic or post acute disease may, 
by their own efforts, preserve or resume optimal functioning in society and, through improved health 
behaviours, slow or reverse progression of disease. 
45
.” 
In The United States, The Lifestyle 180 programme 
56
 was launched at the Cleveland Clinic in 2008 
aiming to tackle the burden of chronic disease by focusing on prevention of chronic disease and 
improved management of diagnosed chronic disease patients through implementation of a holistic set 
of interventions including correct nutrition, physical activity and stress management 
56
. A study by 
Ricanati et al (2011) evaluated The Lifestyle 180 programme. The programme used class based 
exercise sessions and on-going follow-ups with its patients for a minimum period of 6 weeks. Results 
showed that engagement in such a lifestyle intervention programme had significant improvements in 
biometric and laboratory measurements and a reduction in prescribed medications at a 30 week 
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assessment 
56
. Ultimately, this is the main objective of any chronic disease rehabilitation programme; 
to achieve reductions is chronic disease related risk factors and enable the patient to obtain a better 
understanding and control of their chronic condition. 
A review by Blue and Black (2005) examined 17 well-controlled studies.  The studies targeted 
physical activity and healthy eating among adults in the community, worksite and medical clinic 
settings. Goals were set at either weight loss or diabetes prevention and interventions consisted of a 
combination of educational and behaviour change strategies. Eleven of the 17 studies showed 
significant positive changes in physiological outcomes, physical activity and healthy eating 
behaviours. The outcomes were maintained during follow-up periods of up to 5 years 
57;58
. 
Part of the challenge in treating patients with chronic disease with lifestyle intervention programmes is 
the maintenance of the behaviour changes that take places during the programme. According to the 
review by Marcus et al (2006) structured exercise programmes have dropout rates ranging from 9-87 
% 
57
. This is indicative of the challenges related to compliance and adherence amongst chronic 
disease patients seeking to initiate change and incorporate physical activity into their activities of daily 
living 
57
.  
A further review by Morgan (2005) concluded that sustainability of appropriate physical activity levels 
are important for the maintenance of physiological benefits, and the use of follow up consultations are 
important to ensure physical exercise is sustained and not just used for short term goals 
59
.  
A suggestion by Kendall & Rodgers (2007) 
60
 and their study concluded, that merely being offered an 
intervention and knowing that on-going group support is available, may assist individuals to improve 
their adherence to interventions. They found that a self-management group intervention failed to 
influence mood, thinking, social roles and self-efficacy. However the intervention tended to maintain a 
stable level of adjustment over the first year after an event 
60
.  
 
Another aspect to consider when presenting a lifestyle intervention is the environment and medium in 
which the programme takes place, especially the exercise component. This has shown to impact on 
the success or failure in adherence to the programme and maintenance of behaviour changes after 
completion of the programme in treating chronic disease patients 
61
.A study by King et al (1992) 
62
 
examined home-based exercise versus group based exercise. Higher adherence rates were seen in 
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home-based exercising participants over a two year follow-up. Participants had greater flexibility in the 
choice of physical activity and whether to complete it intermittently or in one single bout. 
Studies by Clark et al
63
 found that shorter programmes delivered by non-specialist health care 
professionals in non-clinical settings were least effective in reducing mortality 
63;64
. This is further 
supported by Eakon et al (2000) who found that interventions conducted in healthcare settings and 
delivered by specialized healthcare providers increased physical activity over a shorter period of time 
44;57
. From this evidence, it is important to understand that the medium in which the lifestyle 
intervention takes place, follow up appointments to help patients feel accountable and, to reinforce the 
positive changes they continue to make as well as the settings (clinical or home based) all impact 
adherence and maintenance of lifestyle changes. 
Each lifestyle intervention programme incorporates different components in which patients acquire 
skills such as self-monitoring, goal setting and self-motivation that increase their physical activity 
levels and long term adherence to on-going changes. Programmes that are too short in duration 
possibly don’t allow individuals enough time to adjust to their new changes and when they continue 
on their own they have not fully acquired the skills and knowledge to do so. Specialists and 
professionals working with chronic disease patients will also be able to provide these individuals with 
valuable knowledge and education about the purpose for each component as well as the appropriate 
environment in which this should take place. Chronic disease patients need to understand that 
making lifestyle behaviour changes is a process and requires time, and that there are no short cuts in 
rectifying poor health behaviours. 
Part of the purpose completing a lifestyle intervention and assisting individuals in modifying their 
lifestyle behaviour to improve on their health status, is to ensure individuals don’t become dependent 
on such programmes and interventions and must be educated about how to continue on their own 
after completion of their programme. This is often a transition that individuals struggle with and revert 
back to their old habits. It is important that as a part of these interventions, participants are 
encouraged to exercise on their own, within safe limitations and demonstrate their ‘new’ behaviours. 
Research has shown that lifestyle interventions could be delivered and enhanced by new 
technologies such as interactive computer-mediated programs, telephone, or computer web-based 
forums to reduce these relapses 
61
.  Programmes that have used new technologies and demonstrated 
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improvements in health related outcome variables include an Australian study by Vale et al (2003)
65
, 
which identified the benefits of telephone delivered, pedometer-based interventions on physical 
activity amongst people with cardiac disease. Results showed the method to be effective in reducing 
body mass index (BMI) 
64;65
. 
The CHOICE programme by Neubeck et al
66
 was also found to be effective in improving cardiac risk 
factors in people with cardiac disease, who had previously not attended any rehabilitation or lifestyle 
interventions. The programme included a one-on-one consultation and four follow up phone calls 
64;66
 
Results showed improved risk factors including blood pressure, total cholesterol and body mass index 
66
. 
Yet, despite all of the evidence supporting the benefits of lifestyle interventions, challenges still 
remain. Patients need to maintain their lifestyle changes and clinicians and health care systems need 
to encourage and educate patients to develop these strategies and incorporate these interventions as 
part of their treatment and prevention plan, and refer patients into existing programmes 
61
. 
 
2.7 Barriers to lifestyle changes and adherence 
The existing knowledge of barriers to chronic disease risk control is primarily from studies that have 
indicated the patient’s financial difficulties to afford care, physician failure in appropriate clinical 
treatment, and insufficient self management support for patients and patient non adherence to 
medication 
36
. 
In other studies, statistics showed that only 22 % of the population in America adhered to regular 
exercise and only 3 % adhering to healthy diet, regular physical activity, no tobacco use and 
maintaining normal body weight. This evidence highlights the importance of identifying and 
understanding these barriers to chronic disease and risk factor control 
67
.  
There have also been gains in understanding the resistance to healthier changes from self reports by 
patients which highlight the same reasons of financial difficulties, poor coherence between treatment 
protocols and perceived health and complicated medical treatments 
36
.  
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Studies by Crossen et al investigated these barriers by looking at the perceptions of physicians. 
Common themes emerged as barriers to cardiovascular disease risk control 
36
:  
- The presence of their co-morbidities and pain 
- Poor patient “motivation” to take care of themselves 
- Healthcare system barriers preventing physicians from delivering care such as lack of 
communication with other healthcare providers and lack of financial support 
- Difficulties in finding healthcare providers who provide these services, location and time 
- Physicians’ frustration with patients’ poor motivation for maintaining good health, their 
resistance to treatment prescriptions and adherence 
- Physician’s belief that these barriers are outside of their control 
By creating awareness and a better understanding of the challenges physicians face in ‘convincing’ 
patients to make healthier changes could impact positively in the treatment interventions and regimes 
used for patients 
36
.  
Barriers to an active lifestyle and subsequent strategies to overcome them, were investigated by 
Brinks et al (2011) 
67
. The following factors were identified as contributing towards low adherence 
rates included time and financial constraints, psychosocial factors, and physical limitations. The study 
suggested healthcare providers should make use of counselling strategies to assist patients in 
overcoming these barriers. Motivational interviewing, goal setting and identifying physical and 
psychosocial limitations were suggested to improve exercise and lifestyle change adherence 
67
.  
To improve on the poor referral rate it is important to understand the barriers to appropriate care, 
which include issues of patient referral and enrolment in such programmes and the availability and 
access to chronic disease rehabilitation among women, minorities, and older individuals 
36
. 
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Table 2.1 Factors contributing to low referral, enrolment and completion of chronic disease 
rehabilitation programmes 
68
 
 
 
 
 
 
 
 
 
 
2.8 Referral into rehabilitation programmes 
Although there is evidence to support the benefits of chronic disease rehabilitation programmes and 
interventions, the use of these programmes is still very low 
69
. The referral of patients in need of a 
lifestyle intervention is infrequent due to various factors including financial costs, awareness of 
healthcare providers specializing in these interventions and the involvement and co-ordination of 
medical insurers and health care organizations. A major role of primary health care organizations and 
medical insurers is to communicate and create networks of referral services to support patients 
engaging in lifestyle interventions. Brief interventions implemented by general practitioners are not 
sufficient to achieve the necessary changes needed in high risk patients with chronic disease 
70;71
. 
Grace et al (2011) 
72
 determined the optimal strategy to maximize cardiac referral, enrolment and 
participation. The study evaluated three referral strategies compared with usual care of “automatic” 
referral via discharge card or electronic record, health care provider liaison only, or a combined 
approach. In-patients with coronary artery disease were used as the study sample. A one-year follow 
Factors associated with limited referral and enrolment in chronic disease rehabilitation 
programmes: 
 Gender (females) 
 Older age 
 Racial/ethnic minority group 
 Lack of or limited medical insurer funding 
 Low socioeconomic status 
 Poor level of education 
 Poor health education 
 Lack of perceived need for chronic disease rehabilitation 
 Language 
 Cultural beliefs 
 Work-related factors 
 Limited social support 
 Healthcare system factors 
 Lack of referral 
 Insufficient enrolment after referral 
 Strength of physicians support for chronic disease rehabilitation 
 Chronic disease rehabilitation programmes 
 Lack of programs in rural areas and low-income communities 
 Programme operation hours 
 Transportation problems 
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up assessed the patient’s cardiac rehabilitation utilization. The study concluded that automatic referral 
combined with a patient discussion achieved among the highest rates of cardiac rehabilitation referral. 
The implementation of such strategies could ensure that more patients being treated for cardiac 
disease would have access to and realize the benefits of cardiac and chronic disease rehabilitation 
programmes 
72
.  
Other studies have also shown the enormous impact that physician’s recommendations to patients 
have on influencing patients’ lifestyle behaviours 
61
. This provides a huge window of opportunity for all 
physicians to provide information to their patients in making lifestyle changes and engaging in a 
lifestyle intervention as part of prevention and treatment for chronic disease. Unfortunately, physicians 
often underestimate the importance and power of their role as health behaviour change counsellors 
61
. Thus part of the inconsistency in referral of patients can be explained by the physicians’ 
endorsement of such programmes and the healthcare providers in hospitals to correctly refer patients 
73
. A study by Brown et al (2009) 
37
 found hospital programmes had a higher referral rate than the 
national average. The study highlighted that increasing referrals into a cardiac rehabilitation 
programme is but a single factor but enrolling, adherence and completing these programmes continue 
to provide a major challenge to healthcare providers 
68;74
.  
A further review by Baladay et al (2011) 
68
 gave insight into different models for delivery of 
rehabilitation as well as referral strategies into these programmes. They highlighted that patients are 
very often not referred to participate in a rehabilitation programme and therefore hospital based 
intervention programmes that have automatic referral from physicians have a much higher referral 
and enrolment rate 
68;75
. 
Suaya et al (2007) 
76
 studies found only 14 %-35 % of myocardial infarction survivors and 31 % of 
coronary bypass graft surgery patients attend cardiac rehabilitation 
55;76
. Referral rates were also 
found to be lower in women, older adults and ethnic minorities 
69
. These groups are also less likely to 
participate in cardiac rehabilitation and more likely to die within 5 years after an initial myocardial 
infarction 
68;76
. 
Suggestions to improve low referral rates and the utilization of interventions and rehabilitation 
programmes by Crossen et al
36
 are to create patient-specific programmes (such as programmes for 
women, over 60’s etc.), different delivery methods of the programme (e.g. Home-based or internet 
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based programmes), and increase the medical insurance coverage of these programmes to assist in 
overcoming these adherence and referral issues 
36
. 
Therefore, there is a need for a better understanding of referral strategies and barriers to lifestyle and 
behaviour change. Improved methods to identify of these ‘red flags’ when a patient is referred and 
enrolled for a chronic disease rehabilitation programme are also needed 
77
.  
 In Australia, strategies and referral rates have been enhanced, with the NSW Department of Health 
implementing strategies such as facilitating inpatient visits by family and appropriate healthcare 
providers ensuring them of the benefits of rehabilitation, identifying barriers such as transport or 
financial constraints, follow up phone calls after a patient has been discharged again and possible 
home visiting services 
55
. 
An established model that has been used in Western Australia to enhance access to chronic disease 
rehabilitation has had 81 % participation and completion rates for cardiac rehabilitation patients 
55
.  
Reasons for their success has been attributed to policies that allow for recruitment into their 
programme without a medical referral, enabling the rehabilitation to be incorporated into the medical 
pathway, inpatient visits to potential patients and follow up phone calls on discharge 
55
. 
 
2.9 Behaviour change 
Understanding the theory of behaviour is very important in working with patients with chronic disease 
and their rehabilitation. Current knowledge of validated behaviour change theories provides 
healthcare providers with an understanding of the patient’s responses, actions and challenges they 
face in changing behaviour. With this knowledge, healthcare providers are better able to support 
patients through these stages and processes 
55;78;79
. 
To successfully achieve ideal lifestyle behaviour modifications requires individuals to make conscious 
decisions to change 
80
. Many individuals struggle to implement new health behaviours because it 
requires changing their current behaviour and habits. Within lifestyle interventions, such as The 
Chronic Disease Risk Reversal and Reduction Programme, behaviour modifications are incorporated 
to help increase the adherence to, and effectiveness of risk related behaviour changes. One of the 
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goals with behaviour modification is to first identify existing behaviours that contribute to increased 
health risk. Understanding the patient’s barriers to change and adherence also need to be understood 
to allow for modifications to take place. Part of this process is also the relationship developed 
between the patient and healthcare provider. In patient-centred programmes, it is important that the 
healthcare provider displays an understanding of the patient’s condition and allow the patient to feel in 
control and part of their treatment process. The patient needs to show self motivation for change and 
leadership in managing their treatment 
81
. Studies by Armstrong et al (2011) demonstrated the 
positive effect of behaviour modification, specifically motivational interviewing in treating obese 
patients who were unsure about making change 
82
.  
Changes to behaviour should be goal orientated and involve small changes. Goals should be applied 
using the SMART principle (setting goals that are specific, measurable, realistic and time-bound.) This 
principle enables individuals to be involved with their treatment as well as be realistic about their 
expectations of treatment and making change 
83
. 
This process of changing behaviour is very complex and is based on the individual’s readiness to take 
action. The Stages of Change model for behaviour change, describes this as a process that occurs 
over time and in stages. It states there are five stages, each one representing a different time and 
task. To reach the next stage, the individual needs to spend time completing the tasks. Norcross et al 
(2011) outline the five stages as follows 
84
: 
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Table 2.2  Transtheoretical Model of the stages of change in behaviour 
84
 
 
Stage 
 
Readiness to change 
 
Description 
 
Pre contemplation 
 
No intention to change 
 
 
Individual unaware of, or 
underestimates the problem.  
 
Contemplation 
 
Contemplating change 
 
Individual aware that problem 
exists but uncommitted to taking 
action. 
 
Preparation 
 
Planned change 
 
Individual has a definite time set 
to take action and might be 
making small changes 
 
Action 
 
Change has been made to 
behaviour and/or environment 
 
Individual has successfully 
altered behaviour for a period of 
less than 6 months. 
 
Maintenance 
 
New behaviour is maintained 
and relapse has not occurred 
 
Individual consistently engages 
in new behaviour and works to 
prevent relapse (> 6 months 
from initial change) 
 
Another theory that can also be used in lifestyle interventions and by healthcare providers to enable 
patients to apply change is the Social Cognitive Theory. This theory stipulates that individual 
characteristics, current behaviour patterns and their environment influence behaviours. According to 
this theory, for an individual to successfully make change they need to have the motivation and ability 
to create an environment that will allow behaviour modification 
85
. The individual needs to show a high 
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level of self-efficacy. Social Cognitive theory also includes the individual’s ability to change is linked to 
how capable they are in dealing with environment stressors 
86
. 
There are many concepts shown in both the Stages of Change model and the Social Cognitive theory 
that allow for both theories to be useful for healthcare provider who treat chronic disease patients. A 
study by Wadden et al
87
 (2005) showed that the inclusion of behaviour modification, in addition to 
physical activity and dietary interventions resulted in greater success of weight loss as well as the 
maintenance of weight loss 
87
. 
The use of the these theories as well as motivational interviewing in lifestyle interventions will help 
create patient-centred programmes aiming to reduce risk factors for chronic disease. Behaviour 
modification, along with physical activity and dietary intervention should be used in conjunction with 
one another to allow for the best possible outcome in chronic disease treatment and prevention. 
 
2.10 Conclusion 
In conclusion, the burden and impact of chronic disease globally and within South Africa will cripple 
not only the healthcare system but also the workforce of healthy workers and essentially impact 
negatively on the economy. Factors contributing to the increase of chronic disease are directly related 
to poor lifestyle behaviour choices leading to the increase in risk factors associated with chronic 
disease. 
Interventions designed to treat chronic disease are shifting towards patient-centred programmes to 
allow for the existence of more than one chronic disease treatment in patients with multiple co-
morbidities. The literature has shown the positive effect these programmes with regard to reducing 
risk factor status as well as changing risky behaviours. Multi-component interventions that include 
physical activity, dietary and stress management have shown the greatest improvements in patients 
with chronic disease and maintenance thereof. 
This thesis aims to examine the difference in rehabilitation outcomes for a group of patients with 
chronic disease who have been referred and funded by their medical insurer and compare this group 
to a group of patients who self-referred and funded themselves through a 12 week (36 sessions) 
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chronic disease lifestyle intervention programme. It is hypothesized that patients will show 
improvements in the outcome variables and decreases their risk factor levels. However, when 
comparing the medical insurer referred and funded group of patients to the self funded group of 
patients, it is hypothesised that the self funded patients will show greater improvement in 
physiological variables because they might be in a more advanced stage of their readiness to change 
as they have paid for the programme personally and therefore have a greater “vested interest” in their 
compliance and extent of participation. 
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CHAPTER 3 
The effects of a comprehensive lifestyle modification programme in cardiac 
patients: A comparison of rehabilitation outcomes in insurer-funded vs. self-
funded patients 
 
3.1 Introduction 
 
More than 50 % of the global deaths are due to chronic non- communicable diseases 
9
. The 
prevalence of these diseases has shown a decline in both industrialized and developed countries but 
has shown an increase in poorer, low income developing countries 
1;2;7
. 
In South Africa, a third of all deaths are due to chronic disease 
1;18
. Cardiovascular disease accounted 
for 11 %; cancer 7 %; chronic respiratory disease and diabetes were 3 % each respectively and 4 % 
to other chronic diseases and injuries 
1;18
. The chronic disease trends within South Africa are affected 
by the HIV/AIDS epidemic and socioeconomic factors such as poverty, urbanization and 
industrialization 
19;20
.  Furthermore, the impact of these chronic diseases is compounded by the high 
injury rate due to violence, high crimes and traffic accidents. Thus, this complex burden of disease 
places an excessive demand on the already stretched health services in South Africa beyond its 
available resources. However, there has been very little recognition given to the severity of the burden 
of chronic diseases of lifestyle in South Africa 
19;88
. 
Both globally and within the South African context, cardiovascular disease is the most prevalent of 
chronic diseases but previous research conducted in this unit (ESSM, University of Cape Town) has 
shown that more than 60 % of patients taking part in chronic disease rehabilitation programme have 
significant co-morbidities 
14;89
. 
Furthermore, our research has shown that besides existing medical co-morbidities, musculoskeletal 
conditions such as osteoarthritis and chronic low back pain are common amongst these patients 
67
. 
Thus, the management of these patients should be patient focused rather than disease focused.  
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
 
 
40 
A comprehensive lifestyle intervention programs focuses on promoting regular physical activity, 
improving dietary factors, managing psychosocial stress, addressing unhealthy social habits (smoking 
and excess alcohol consumption) and providing comprehensive targeted health education. In 
contrast, single disease-management programs often place greater emphasis on the management of 
the complications of one specific chronic disease (e.g. diabetes mellitus), symptoms, and of health-
seeking behaviours 
8;13
. 
Interventions designed to modify and control multiple risk factors can have a favourable impact on the 
progression and even reversal of chronic disease (secondary/tertiary prevention) 
41
. Therefore the 
objective of a comprehensive lifestyle intervention program is to provide patients with information, 
education and skills to enhance their own involvement and ability to participate in the management of 
their own health 
24
. 
Lifestyle intervention programmes have generally shown to be effective 
51;52;54;64;90-94
. Evidence of 
improved lifestyle behaviours was seen in two recent studies 
91;92
 that showed the favourable 
association between lifestyle factors and the reduced risks of hypertension in healthy women aged 
27-44 years old and heart failure in healthy men (mean age 53 years old).  Adherence to lifestyle 
factors, namely, normal body mass index, optimal dietary intake, daily exercise and low alcohol intake 
were shown to be associated with significantly lower incidence of hypertension 
91;92
. 
Although there is evidence to support the benefits of chronic disease rehabilitation programmes and 
interventions, the utilization of these programmes is still very low 
68
. The referral of patients in need of 
a lifestyle intervention programme is infrequent due to various factors including financial costs, 
awareness of healthcare providers specialising in these intervention and the involvement and support 
of medical insurers 
68;74
. 
A major role of primary health care organisations and medical insurers is to communicate and create 
networks of referral services to support patients engaging in lifestyle interventions. Brief interventions 
implemented by general practitioners may not be sufficient to achieve the necessary changes needed 
in high risk patients with chronic disease 
71;72
.  Interventions aimed at improvement and rehabilitation 
of chronic disease should consider all the lifestyle factors and therefore be multi-component in nature, 
and include promotion of regular physical activity, psychosocial interventions, educational aspects 
including dietary modification, risk factor management and monitoring to ensure safe participation in 
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exercise 
71
. Educating referring doctors, organizations and medical insurer funders about programme 
philosophy and cost benefit issues is pivotal in improving chronic disease rehabilitation referral.  
Evidence showed that when patients who were eligible for chronic disease rehabilitation in the United 
States and Canada were asked why they did not attend such programmes, the most frequent 
response was cited as lack of referral into such programmes. Referrals should include all necessary 
information and communication between the patient as well as the healthcare provider and the 
programme they will be enrolling into. Communication and education between the referring doctor and 
the programmes philosophy and costing information must be included as part of this process 
95-97
.  
This type of system does exist in Australia and Canada where patients in need of a lifestyle 
intervention after an event requiring hospitalization are automatically referred for such programmes 
72
. 
The Chronic Disease Risk Reduction and Reversal program (CDRRRP) is a patient centred, 
comprehensive lifestyle intervention programme based at the Sport and Exercise Medicine Clinic that 
is located at the Sports Science Institute of South Africa. The programme is designed for patients with 
established chronic disease including cardiovascular disease, diabetes mellitus, chronic respiratory 
disease, cancer, fibromyalgia, chronic renal disorders, myopathies, and joint degeneration. 
This medically supervised programme involves a systematic assessment followed by a lifestyle 
intervention that includes supervised exercise to increase the functional capacity and psychological 
well-being of patients. Upon entering the programme each patient is screened and risk stratified by a 
Sport & Exercise Medicine Physician. Following risk-stratification, patients are further assessed by a 
biokineticist before commencing their supervised exercise sessions. 
Patients enter or are referred to the programme through varying channels. Most patients are self 
referred having learned of the programme by word-of-mouth or through marketing, or advised to 
attend by their treating physician. These patients typically pay for the programme themselves and are 
therefore self-funded. Some of these patients may attempt to claim back the costs of the programme 
with varying levels of success. Recently, one medical insurer (Fedhealth) has adopted a unique 
strategy that involves automatic patient identification, notification, referral and payment for patients 
who are part of their scheme within a 20 km geographic radius of the Programme.  It is possible that 
as the programme is not paid for out of the patients own pocket and they are not self referred to the 
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programme but referred by a third party (the fund) that the motivation for adherence, effort and 
therefore adaptation to the programme might not be the same as the self funded and referred group. 
Thus, the main aim of this study is to compare physiological, functional and metabolic outcomes 
between the group of patients referred and funded to the CDRRRP by their medical insurer, (FH) 
versus a self funded and referred group (SF) of patients with chronic disease, to determine if any 
differences exist in these groups with respect to their outcomes achieved after completing the 12 
week programme. A secondary aim of this thesis was to determine the magnitude of changes in the 
combined group of patients throughout the duration of the programme.  
3.2 Methods 
3.2.1 Type of study 
This study is a retrospective cohort study to determine if there were differences in outcomes between 
patients that were funder identified and funded (FH) and a cohort of patients who were self referred 
and self funded (SF) following a 12-week comprehensive lifestyle intervention programme..  
3.2.2. Patient recruitment 
As previously described, the chronic disease lifestyle intervention programme of the Sport and 
Exercise Medicine Clinic, admits patients with a variety of chronic disease states including chronic 
obstructive pulmonary disease, diabetes, cancer, frailty, depression, chronic arthritis and other 
conditions. Patients entered the programme through two points of entry. The first group of patients 
were referred by a single private medical insurer (Fedhealth – FH group) who opted to pro-actively 
refer patients with certain pre-determined ICD-10 codes within a 20 km radius of the Institute. The 
second group were either self or cardiologist referred patients who undertook to self fund the 
programme (SF group).  
In this study, to ensure that both groups are similarly matched by diagnosis, only patients who entered 
the programme with an ICD-10 code for cardiovascular disease (acute myocardial infarction ICD10 
code: I21, angioplasty ICD10 code: Z95.5, stent placement ICD10 code: Z95.5, bypass surgery 
Z95.1, pacemaker ICD10 code: Z95.0) as their primary diagnosis were entered and analyzed. The 
clinical data was audited from consecutive patients matching these codes who were entered into the 
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programme between 2006 -2011.  The total number of patients who entered the programme and 
matched the inclusion criteria during the study period was 209. Of the 209 individuals who entered 
into the programme, 25 did not complete the programme and 5 had incomplete records. These 
participants were therefore excluded from the analysis (Table 3.1). Reasons for withdrawal included a 
re-event or illness, financial constraints, difficulty in committing to the dedicated class times, location 
and accessibility of the programme. Thus, 179 participants with complete data were studied.  There 
were 44 participants in the FH group and 135 participants in the SF had (Table 3.1) 
Table 3.1 Recruitment of participants  
Cardiovascular Patients 
Number of 
Individuals with 
complete data  
Number of Individuals 
with incomplete data  Total 
Dropouts No Records 
All participants 179 25 5 209 
SF group 135 21 4 160 
FH group 44 4 1 49 
 SF = Self funded group, FH = Fedhealth group 
3.2.3. Clinical assessment 
- History and physical examination 
Upon entry to the programme, all patients underwent a clinical assessment with a sports 
physician at the Sports and Exercise Medical Clinic located at the Sports Science Institute of 
South Africa.  During this evaluation the doctor performed a thorough medical history and physical 
examinations as well as necessary special investigations in order to risk stratify the patient. This 
was conducted in order to determine co-morbidities necessitating other rehabilitation 
considerations or if contraindications to exercise testing and participation existed and also to 
determine risk factors or pre-existing musculoskeletal conditions which would necessitate 
modifications to the patients exercise prescription.  
- Stress electrocardiogram (ECG) 
A requirement for patients at evaluation was to have a recent (within the last 3 months) multistage 
symptom/sign limited maximal effort electrocardiogram (ECG). The sport physician assessed the 
patients stress ECG if this had been performed by their cardiologist. If the ECG was not done or 
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the quality of the effort ECG was not adequate, the patient then completed a stress ECG at the 
Sports and Exercise Medicine Clinic located at the Sports Science Institute of South Africa. 
Depending on the risk status of the patient either the Bruce protocol or Modified Bruce protocol 
was used according to the criteria determined by the American College of Sports Medicine 
(ACSM)
42
.  The treadmill used for this test was a Technogym Medical Range treadmill 
(Technogym, Pentasystems, and Johannesburg). During this test, systolic and diastolic blood 
pressure was monitored every three minutes using a Welch Allyn FlexiPort
TM 
sphygmomanometer 
(Welch Allyn, Skaneateles Falls, NY) and Welch Allyn stethoscope (Welch Allyn, Skaneateles 
Falls, NY). The sphygmomanometer was placed on the patients left arm and a blood pressure 
was recorded while they continued with their stress test. A standard 12-lead electrocardiogram 
(ECG; Mortara Instrument, Inc. Milwaukee, Wisconsin) was used to monitor the patient 
throughout the protocol. Heart rate was recorded every minute during the stress ECG using the 
above system.  The stress ECG test was terminated  according to the ACSM indications for test 
termination 
42
. The purpose of completing a stress ECG before joining the CDRRRP was to 
ensure the appropriate exercise intensity is prescribed by using a safe and effective heart rate 
limit. 
Patients who had absolute contraindications to exercise testing and exercise training 
42
 were 
referred back to their cardiologist for further management of their condition and were asked to 
return for reassessment once their condition had stabilized. These conditions included; recent 
changes in resting ECG, unstable angina, acute or chronic heart failure, uncontrolled ventricular 
and atrial arrhythmia’s, third degree AV block without a pacemaker, suspected or known 
dissecting aneurysm, narrowed aortic stenosis, myocarditis or pericarditis, thrombophlebitis or 
intra-cardiac thrombi, recent systemic or pulmonary embolus, acute infections, or significant 
emotional stress.  Relative contraindications to programme initiation included inadequately 
controlled hypertension: resting diastolic blood pressure > 110 mmHg or resting systolic blood 
pressure > 200 mmHg, moderate valvular disease, electrolyte abnormalities, fixed rate pace-
maker , frequent or complex ventricular ectopy, ventricular aneurysm, uncontrolled metabolic 
disease (i.e. diabetes), chronic infectious disease, neuromuscular, musculoskeletal, or 
rheumatoid disorders which could be exacerbated by exercise 
42
. 
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Patients who did not have any of the above contraindications underwent further assessment that 
included anthropometrical assessment and tests of functional capacity. 
 The purpose of this initial evaluation is to ensure safe and individualized exercise prescription and 
participation in the programme.   
3.2.4. Measurement of outcome variables 
3.2.4.1 Physiological variables 
Physiological variables included the assessment of resting heart rate, blood pressure and 
anthropometric variables.  
- Resting heart rate and brachial blood pressure 
A seated resting heart rate and blood pressure was measured after the participant sat and relaxed for 
a period of five minutes. Heart rate was measured by fitting the patient with a heart rate monitor belt 
to their chest and wrist watch (Polar Heart rate monitor, model FT2, Finland).The right arm was then 
lifted so that the brachial artery was level with the heart. A Welch Allyn FlexiPort
TM 
sphygmomanometer cuff (Welch Allyn, Skaneateles Falls, NY) was wrapped around the participant’s 
upper arm, just above the elbow and a Welch Allyn stethoscope (Welch Allyn, Skaneateles Falls, NY) 
was placed on the hollow of the elbow, over the brachial artery. The cuff pressure was inflated to 160 
mm Hg. The cuff pressure was slowly released at a rate equal to 2 to 5 mm Hg per second. Systolic 
blood pressure was the point where the first of two or more Korotkoff sounds were heard and diastolic 
blood pressure was the point before the disappearance of the Korotkoff sounds 
42
. 
Anthropometric assessment included height and weight measurements and calculation of body mass 
index (BMI). Furthermore, skin folds (4 site: triceps; bicep; subscapular and suprailiac), waist and hip 
circumferences were measured and a waist-to-hip ratio was calculated. 
- Body, height and body mass index (BMI) 
Body weight was measured using a TCS-A 300 kg Platform Scale (Clover Scales, Maitland, and Cape 
Town) and height was measured using a Leicester 214 portable stadiometer. (Lifemax, 
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Randparkridge, Johannesburg). Body Mass Index (BMI) was calculated based on these two 
measurements as described by the ACSM 
42
. 
BMI = Weight (kg)/Height (m)
2
 
- Body fat percentage 
Skin folds were measured using a Harpenden Skin fold Dial Gauge Calliper. (Lifemax, Randparkridge, 
Johannesburg). This is performed to provide an indication of body fat percentage, which was 
calculated by using the Durnin and Womersley Skin fold Method. Sum of 4 skin fold equation.) 
98
. This 
method involved the measurement of skin folds on the following 4 sites: Biceps, Triceps, Subscapular 
and Suprailiac.  
- Waist-to-hip ratio. 
A standard tape measure was used to measure the patient’s waist and hip measurement. The patient 
was asked to stand upright, feet together and arms placed out to the side, whilst breathing normally. 
The hip measurement is taken from a lateral view at the widest part of the gluteus maximus. The 
waist measurement is then taken at the base of the rib cage in line with the navel. A ratio was then 
calculated from the two measurements using the following calculation 
42
: 
Waist-to-Hip ratio:  Waist measurement (cm) 
Hip measurement (cm) 
 
3.2.4.2 Functional variables 
The tests of functional capacity used to evaluate patients both at entry and after 12 weeks were the 6 
minute walk test and the sit and reach test as an assessment of flexibility. 
- The six minute walk test 
This test was conducted to assess both functional capacity and heart rate response and recovery 
99-
101
. Patients were instructed to walk around a 140 m track for a period of 6 minutes and cover as 
much distance as possible without becoming symptomatic. Prior to starting the test, blood pressure 
and heart rate was measured and patients were fitted with a heart rate monitor (Polar Heart rate 
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monitor, model FT2, Finland) to ensure that they exercised within an acceptable heart rate range. 
Heart rate was also recorded at each lap, as well as at the termination of the test. Time was 
monitored as each lap that was completed. A 1 minute seated recovery heart rate was also recorded. 
- Sit and reach test 
This test gave an indication of lower back and hamstring flexibility 
102
.  A standard measured sit and 
reach box of 50 cm was used 
42
. Patients removed their shoes and started the test with their feet flat 
against the box and legs straight. The patient started from an upright position, arms straight; keeping 
middle fingers together and slowly breathed out and leaned forward along the measured box until 
they could not reach any further, whilst keeping their legs straight 
42
. They then returned to the start 
position. The test was repeated 3 times and the best score of 3 was used. The score was expressed 
in centimetres (cm). 
3.2.4.3 Metabolic variables 
Blood test-results upon entry to the program were obtained from the patient’s cardiologist and/or 
general practitioner and the results reviewed. The blood tests analyzed for the purpose of this study, 
were fasting total cholesterol, LDL, HDL, triglyceride and fasting glucose concentrations. Blood tests 
were conducted using private pathology laboratories, namely Pathcare (Goodwood, Cape Town) and 
Metropolis (Milnerton, Cape Town) according to the South African National Accreditation System 
(SANAS PM SANAS Policy Manual SANAS A01 References, Acronyms and Definitions ISO 15189 
Medical Laboratories – Particular requirements for quality and competence ISO/IEC 17025:2005 
General requirements for the competence of testing and calibration Laboratories, 2010). Patients 
were requested to repeat these blood tests (which were important for risk-factor assessment) after 12 
weeks on the programme. 
 
3.2.3 Psychological Screening 
Upon entry into the programme each participant completed a screening evaluation consisting of 
several psychological questionnaires, namely the Conner-Davidson Resilience Scale (CD-RISC), 
Temperament & Character Inventory (TCI) and Tridimensional Personality Questionnaire (TPQ), 
Kessler Psychological Distress Scale (K10), Life Events Scale, SSSI, STAIT. The purpose for these 
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questionnaires was to assess the patient’s personality type, and provide a marker of anxiety, 
depression and psychosocial stress. Patients who were assessed as being at risk with respect to 
these parameters were referred for further psychological counselling. The data from these 
questionnaires are not reported in this study. 
 
3.2.4 Intervention programme 
Patients from both groups attended the CDRRR program for 12 weeks (36 sessions). CDRRP is a 
medically supervised and closely monitored lifestyle intervention programme that is based at the 
Sport and Exercise Medicine Clinic that is located at the Sports Science Institute of South Africa. It is 
presently in its 16
th
 year and over 600 patients completed it. The programme consists of the following 
components: risk screening, supervised physical exercise sessions and monitoring during exercise, 
dietary education and intervention, educational modules provision, injury prevention and 
psychological/psychosocial stress assessment and intervention. The programme biokineticist in 
consultation with the Sport and Exercise Medicine physician prescribed the intensity, duration, 
frequency, mode and progression of exercise as well as injury prevention strategies for each patient. 
Personalized exercise programmes were designed and the patients entered phase 1 namely, the 
MediFit Elite Care 12 week (36 session) Programme. The programme compromised of 36 one hour 
exercise sessions, held three times a week at either 7-8am or 2-3pm, Monday, Wednesday and 
Friday. There were 6 components to the exercise training; cardiovascular fitness, muscular strength 
muscular endurance, flexibility, core stability and proprioception exercises. These components also 
formed part of the injury prevention aspect. Patients were taught the correct techniques and exercises 
for core strengthening and stability, as well as individualized exercises specific to their orthopaedic 
conditions. The main aim of this program was to increase functional capacity and emotional wellbeing 
of each patient and encourage the maintenance of healthier lifestyle and behaviour modifications in 
attempting to reduce chronic disease and related disabilities. 
The educational modules comprised of weekly tutorials that were handed out to each patient during 
their exercise session. During the sessions for the week, the doctor and other staff on duty had the 
opportunity to discuss these topics and their relevance to improving health status and chronic 
disease. There were twelve topics, one for each week of the rehabilitation programme. Topics 
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included introduction to lifestyle and diseases of lifestyle, cardiovascular disease, exercise training 
and monitoring, “when not to exercise”, chronic respiratory disease, diabetes mellitus, cancer, 
metabolic syndrome, hypertension, dislipidaemia, arthritic conditions, depression, osteoporosis, 
obesity, and low back pain. Relaxation, breathing and mindfulness based short interventions lasting 
10 minutes were given at regular intervals during the programme and patients were encouraged to 
continue their own practice of these techniques by themselves at home. 
The dietary intervention involved referring patients to the dieticians within the Sport Science Institute 
of South Africa for a comprehensive, individualised dietary consultation. 
This study was approved by the Human Ethics Research Committee of the University Of Cape Town 
Faculty Of Health Sciences (REC REF 332/2007).  All patients that engaged in the programme 
provided written informed consent prior to participation in the lifestyle intervention programme. The 
patients’ personal and medical information was kept within the confines of the CDRRRP database 
and was not disclosed in any published or written material resulting from this study. 
 
3.2.5 Statistical analysis  
The statistical analysis of the study was conducted by the Biostatistics Unit of the Medical Research 
Council of South Africa (MRC).  All data was collected and entered into an excel spreadsheet. The 
data was analysed using R
1
, an open source statistical programming language. (R Development Core 
Team: A language and Environment for Statistical Computing. R foundation for Statistical Computing, 
http://www.R-project.org)  
Firstly to determine whether the programme had an effect on the above mentioned physiological 
outcomes, a paired t-test, testing for a non-zero difference in the outcome measurements between 
the first testing occasion (T1) and second testing occasion, 12 weeks later (T2) was carried out. 
Secondly, T-tests were performed to determine whether there is a difference in the impact of the 
programme (T2-T1) between the FH and SF group. T-tests were also used to test for a difference in 
the baseline measurements between those who completed the programme and those who did not. 
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Thirdly, to determine whether the data is missing at random with respect to the outcome variables, for 
each outcome, the baseline outcome (response at time point T1) was regressed against the 
missingness at time point T2, medical funder status and the interaction between the two.  
Fourthly, Chi square tests were performed to test for an association between completion status and 
medical funder status with and without the individuals with no records. To determine if there was an 
association between medical funder status and the absence of data for each outcome, chi square 
tests were also performed. 
Lastly, Fisher tests were conducted to test for differences between the two groups with respect to 
gender, completion status, medications, number of deceased, and the following risk factors: high 
blood pressure, hypercholesterolemia, diabetes, family history, overweight, sede tary, and smoker 
status. 
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3.3. Results 
3.3.1 Demographics, disease profile, risk factors and medications use in all 
participants and in the FH and SF groups 
The demographics of all participants, the Fedhealth group (FH) and the Self funders group (SF) is 
depicted in table 3.2 
Table 3.2 Demographics of all participants, the FH group and SF group  
  All ( n = 179) FH (n = 44)  SF (n = 135) P-value 
Age (years) 59 (12) 59 (11) 59 (13)  ns 
Male (%) 86 82 87  ns 
Height (m) 1.7 (0.1) 1.7  (0.1) 1.7 (0.1)   ns 
Weight (kg) 87.9 (18.4) 85.4 (16.9) 88.7 (18.7)  ns 
BMI (kg/m
2
) 29.7 (5.8) 29.5 (5.7) 29.6 (5.7)  ns 
n= represents the number of participants, 
Values are represented by the mean and standard deviation in brackets, except for males, represented 
as a % of the group. 
FH = Fedhealth group, SF = Self funders group. 
% = percentage; m = meters; kg = kilogram; kg/m
2 
= kilogram per meter squared. 
ns = no significant difference between the FH and SF groups 
 
The mean age of all participants was 59 ± 12 years, and more participants in the study were male (86 
%). The mean height was 1.7 ± 0.1 m, weight was 87.9 ± 18.4 kg and body mass index was 29.7 ± 
5.8 kg/m
2
.   
Within the FH group, the mean age of all participants was 59 ± 11 years, and more participants were 
male (82 %). The mean height was 1.7 ± 0.1 m, weight was 85.4 ± 16.9 kg and body mass index was 
29.5 ± 5.7 kg/m
2
.  Within the SF group, the mean age of all participants was 59 ± 13 years, and more 
participants were male (87 %). The mean height was 1.7 ± 0.1 m, weight was 88.7 ± 18.7 kg and body 
mass index was 29.6 ± 5.7 kg/m
2
.  There were no significant differences in age, gender, height, 
weight or body mass index between the FH and SF groups. 
The disease profiles upon entry into the CDRRRP of all participants, the Fedhealth group and Self 
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funders group is depicted in table 3.3 
Table 3.3 The disease profiles of all participants, the FH group and SF group 
Diagnosis  ALL (n=179) FH (n = 44)  SF (n=135) P-value  
1.Cardiovascular disease 175 (97.8)  44 (100.0)  131 (97.0)  ns  
a. Ischemic heart disease  143 (79.9)  41 (93.2)  102 (75.6)  0.01 
 Myocardial infarction 75 (41.9)  24 (54.5)  51 (37.8)  ns  
 Angioplasty with no stent 4 (2.2)  2 (4.5)  2 (1.5)  ns  
 Angioplasty and Stent 66 (36.9)  23 (52.3)  43 (31.9)  0.019 
 Bypass 55 (30.7)  16 (36.4)  39 (28.9)  ns  
b. Arrhythmias  38 (21.2)  8 (18.2)  30 (22.2)  ns  
 Arrhythmia medicated  18 (10.1)  2 (4.5)  16 (11.9)  ns  
 Arrhythmia and pacemaker  18 (10.1)  4 (9.1)  14 (10.4)  ns  
c. Valvular heart disease  18 (10.1)  6 (13.6)  12 (8.9)  ns  
d. Heart Failure  16 (8.9)  2 (4.5)  14 (10.4)  ns  
 Cardiomyopathy (dilated / idiopathic)  8 (4.5)  -  8 (5.9)  ns  
 Ischemic cardiomyopathy  2 (1.1)  -  2 (1.5)  ns  
e.Cardiac transplant  1 (0.6)  1 (2.3)  -  ns  
f. Peripheral vascular disease  8 (4.5)  2 (4.5)  6 (4.4)  ns  
g. Other (including aneurysm)  3 (1.7)  -  3 (2.2)  ns  
2.Chronic respiratory disease 15 (8.4)  4 (9.1)  11 (8.1)  ns  
a. Bronchiectasis  2 (1.1)  -  2 (1.5)  ns  
b. Chronic obstructive pulmonary disease 4 (2.2)  -  4 (3.0)  ns  
c. Asthma  8 (4.5)  3 (6.8)  5 (3.7)  ns  
d. Sarcodosis 1 (0.6)  1 (2.3)  -  ns  
3.Metabollic disease 48 (26.8)  11 (25.0)  37 (27.4)  ns  
a. NDDM  39 (21.8)  10 (22.7)  29 (21.5)  ns  
b. IDDM  5 (2.8)  -  5 (3.7)  ns  
c. Gout 6 (3.4)  1 (2.3)  5 (3.7)  ns  
e. Amiodron induced thyrotoicsis  1 (0.6)  1 (2.3)  -  ns  
4.Rheumatological disease 14 (7.8)  4 (9.1)  10 (7.4)  ns  
a. Rheumatoid arthritis  7 (3.9)  4 (9.1)  3 (2.2)  ns  
b. Fibromyalgia  2 (1.1)  -  2 (1.5)  ns  
c. Hematocrosis  1 (0.6)  -  1 (0.7)  ns  
d. Polyerythromia Ruba Vera  1 (0.6)  -  1 (0.7)  ns  
e. Osteoporosis  3 (1.7)  1 (2.3)  2 (1.5)  ns  
f. Polymyalgia Rheumatica  1 (0.6)  -  1 (0.7)  ns  
5.Immuniological disease 16 (8.9)  2 (4.5)  14 (10.4)  ns  
a. Cancer  14 (7.8)  2 (4.5)  12 (8.9)  ns  
b. Ulcerative Colitis  1 (0.6)  -  1 (0.7)  ns  
c. Myeloproliferative Syndrome  1 (0.6)  -  1 (0.7)  ns  
d. Anaemia  1 (0.6)  -  1 (0.7)  ns  
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6.Cognitive and psychological 9 (5.0)  -  9 (6.7)  ns  
a. Depression  4 (2.2)  -  4 (3.0)  ns  
b. ADHD  1 (0.6)  -  1 (0.7)  ns  
c. Sleep apnoea  3 (1.7)  -  3 (2.2)  ns  
d. Anxiety  1 (0.6)  -  1 (0.7)  ns  
7.Neurological disease 6 (3.4)  1 (2.3)  5 (3.7)  ns  
a. Right side CVA  4 (2.2)  1 (2.3)  3 (2.2)  ns  
b. Peripheral neuropathy  1 (0.6)  -  1 (0.7)  ns  
c. Epilepsy  1 (0.6)  -  1 (0.7)  ns  
8.Orthopaedic conditions 9 (5.0)  3 (6.8)  6 (4.4)  ns  
9.Renal  6 (3.4)  1 (2.3)  5 (3.7)  ns  
10.Other 6 (3.4)  -  6 (4.4)  ns  
FH= Fedhealth group; SF= Self funded group; NDDM = Non insulin dependent diabetes mellitus; IDDM = Insulin 
dependent diabetes mellitus; ADHD = Attention deficit hyperactivity disorder; CVA = Cerebral-vascular accident 
ns = no significant difference between the FH and SF groups 
 
 
Of all participants who entered the programme 79.9 % had ischemic heart disease. The majority of 
these ischemic heart disease participants had myocardial infarction (36.9 %) and an angioplasty with 
stent (36.9 %). Other participants with cardiovascular diseases included those with arrhythmias (21.2 
%), bypass (30.7 %), valvular heart disease (10.1 %), heart failure (8.9 %), peripheral vascular 
disease (4.5 %) and other disease including aneurysms (1.7 %).  In addition, 26.8 % had existing 
metabolic disease, 8.9 % immunological diseases, 8.4 % chronic respiratory diseases, 7.8 % had 
rheumatological diseases and less than 5 % had orthopaedic, cognitive and psychological and 
neurological conditions.   
 
Of the FH group 93.2 % had ischemic heart disease. The majority of these patients had myocardial 
infarction (54.5 %) and an angioplasty with stent (52.3 %). Other cardiovascular diseases included 
those with bypass (36.4 %), arrhythmias (18.2 %), valvular heart disease (13.6 %), heart failure (4.5 
%) and peripheral vascular disease (4.5 %). In addition, 25 % had existing metabolic disease, 9.1 % 
chronic respiratory diseases and rheumatological diseases each and less than 5 % had 
immunological, orthopaedic, neurological and cognitive and psychological conditions.   
Of the SF group, 75.6 % had ischemic heart disease. The majority of these had myocardial infarction 
(37.8 %) and an angioplasty with stent (31.9 %). Other cardiovascular diseases included those with  
bypass (28.9 %), arrhythmias (22.2 %), valvular heart disease (8.9 %), heart failure (10.4 %) , 
peripheral vascular disease (4.4 %) and other including aneurysms (2.2 %).  In addition 27.4 % had 
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existing metabolic disease, 10.4 % immunological diseases, 8.1 % chronic respiratory diseases, 7.4 
% rheumatological diseases, 6.7% cognitive and psychological conditions and less than 5 % had 
orthopaedic and neurological conditions.   
There was a significant difference in the FH group and SF groups with respect to prevalence of 
ischemic heart disease (p: 0.01) and angioplasty with stent placement (p: 0.019). The FH group had a 
higher prevalence of participants with ischemic heart disease and angioplasty with stent placements 
(p: 0.019) when compared to the SF group. 
 
The prevalence of risk factors for cardiovascular disease in all participants and the FH and SF groups 
is depicted in table 3.4. 
 
Table 3.4 The prevalence (% of participants) of risk factors for cardiovascular disease in all 
participants and in the FH group and SF group 
Risk Factor All (n = 179) FH (n = 44) SF (n = 135) P-value 
Gender (males) 154 (86) 36 (82) 118 (87)  ns 
Hypertension 100 (56) 22 (50) 78 (58)  ns 
Hypercholesterolemia 129 (72) 34 (77) 95 (70)  ns 
Diabetes 46 (26) 9 (21) 37 (27)  ns 
Family history 113 (63) 28 (64) 85 (63)  ns 
Overweight 103 (57) 26 (59) 77 (57)  ns 
Sedentary 122 (68) 34 (77) 88 (65)  ns 
Smoker 28 (16) 6 (14) 22 (16)  ns 
FH= Fedhealth group; SF= Self funded group 
Values are the number of participants with percentage of group in brackets 
ns = no significant difference between the FH and SF groups 
 
Of the total 179 participants who entered the programme 56 % were hypertensive, 72 % had elevated 
serum cholesterol concentrations (hypercholesterolemia), 26 % had diabetes mellitus, 63 % had a 
family history of cardiovascular disease, 57 % were classified as overweight, 68 % were sedentary 
and 16 % were smokers (Table 3.4).  
In the 44 participants from the FH group who entered the programme 50 % were hypertensive, 77 % 
had elevated cholesterol (hypercholesterolemia), 21 % had diabetes, 64 % had a family history of 
cardiovascular disease, 59 % were classified as overweight, 77 % were sedentary and 14 % were 
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smokers (Table 3.3). Within the 135 participants from the Self funded group who entered the 
programme 58 % were hypertensive, 70 % had elevated cholesterol (hypercholesterolemia), 27 % 
had diabetes, 63 % had a family history of cardiovascular disease, 57 % were classified as 
overweight, 65 % were sedentary and 16 % were smokers (Table 3.3). There were no significant 
differences in the prevalence of risk factors for cardiovascular disease between the FH group and the 
SF group. 
The medications used by all participants, the FH group and the SF group is depicted in table 3.5. 
Table 3.5 Medication use in all participants, the FH group and the SF group  
Medications  All (n = 179) FH (n = 44) SF (n = 135) P-value†  
Platelet aggregation inhibitors  139 (77.7)  41 (93.2)  98 (72.6)  0.003 
Statin agents 133 (74.3)  40 (90.9)  93 (68.9)  0.003 
Antiarrhythmic agents 10 (5.6)  2 (4.5)  8 (5.9)  ns  
Nitrates  6 (3.4)  6 (13.6)  -  < 0.001  
Calcium channel blockers 17 (9.5)  4 (9.1)  13 (9.6)  ns  
Vitamin K antagonists  19 (10.6)  3 (6.8)  16 (11.9)  ns  
Anti-diabetic agents: Oral  36 (20.1)  7 (15.9)  29 (21.5)  ns  
Beta-receptor blockers  64 (35.8)  17 (38.6)  47 (34.8)  ns  
Alpha- and beta receptor blockers  20 (11.2)  5 (11.4)  15 (11.1)  ns  
Angiotensin receptor antagonists  22 (12.3)  7 (15.9)  15 (11.1)  ns  
Oestrogens  1 (0.6)  1 (2.3)  -  ns  
Bronchodilators  1 (0.6)  -  1 (0.7)  ns  
Folic acid and derivatives  6 (3.4)  4 (9.1)  2 (1.5)  0.033 
Anti-protozal agents (anti-microbials)  1 (0.6)  -  1 (0.7)  ns  
Diuretics  26 (14.5)  4 (9.1)  22 (16.3)  ns  
ACE inhibitors  66 (36.9)  16 (36.4)  50 (37.0)  ns  
Anti-depressants  16 (8.9)  4 (9.1)  12 (8.9)  ns  
Serotonin and noradrenaline reuptake 
inhibitors  
1 (0.6)  -  1 (0.7)  ns  
Endocrine system - Thyroid  3 (1.7)  1 (2.3)  2 (1.5)  ns  
Anti-diabetic agents: Insulin  12 (6.7)  2 (4.5)  10 (7.4)  ns  
Coxibs - selective inhibitors of COX-2  3 (1.7)  -  3 (2.2)  ns  
Hormone replacement therapy  2 (1.1)  -  2 (1.5)  ns  
Glucocorticoids 9 (5.0)  3 (6.8)  6 (4.4)  ns  
Positive iniotropic agents - cardiac 
glycosides 
3 (1.7)  -  3 (2.2)  ns  
Anti-viral agents  1 (0.6)  1 (2.3)  -  ns  
Anti-gout agents 11 (6.1)  1 (2.3)  10 (7.4)  ns  
Antiepileptic agents  3 (1.7)  -  3 (2.2)  ns  
Antimetabolites - Folic acid analogues  3 (1.7)  2 (4.5)  1 (0.7)  ns  
Proton pump inhibitors  11 (6.1)  1 (2.3)  10 (7.4)  ns  
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Hypnotics and sedatives - benzodiazepine 
derivatives   
8 (4.5)  2 (4.5)  6 (4.4)  ns  
Anxiolytics - Benzodiazepine derivatives  5 (2.8)  1 (2.3)  4 (3.0)  ns  
Topical corticosteroids  3 (1.7)  -  3 (2.2)  ns  
Anaesthetic  1 (0.6)  -  1 (0.7)  ns  
Potassium supplements  4 (2.2)  -  4 (3.0)  ns  
Analgesics  1 (0.6)  -  1 (0.7)  ns  
Drugs used in benign prostatic 
hypertrophy  
alpha-adrenoreceptor antagonists  
2 (1.1)  -  2 (1.5)  ns  
Chemotherapy  1 (0.6)  1 (2.3)  -  ns  
nasal decongestant  2 (1.1)  1 (2.3)  1 (0.7)  ns  
Ascorbic acid (vitamin C)  1 (0.6)  1 (2.3)  -  ns  
Tetracyclines  1 (0.6)  1 (2.3)  -  ns  
Anticholinergics  1 (0.6)  1 (2.3)  -  ns  
Antihistamine  1 (0.6)  -  1 (0.7)  ns  
Magnesium supplements  1 (0.6)  -  1 (0.7)  ns  
Androgens - testosterone  1 (0.6)  -  1 (0.7)  ns  
Propionic acid derivatives  1 (0.6)  -  1 (0.7)  ns  
Vitamin B Group  -  1 (0.7)  1 (0.6)  ns  
FH= Fedhealth group; SF= Self funded group 
Values are the number of participants with percentage of group in brackets 
ns = no significant difference between the FH and SF groups 
 
Within the total group of participants, platelet aggregation inhibitors (77.7 %) and statins (74.3 %) 
were the mostly prescribed medications. 36.9 % of all the participants were using ACE inhibitors and 
35.8 % were using Beta-blockers. 20.1 % of all participants were also using oral anti-diabetic 
medications and 6.7 % used insulin 
 
In the FH group, 93.2 % of participants were prescribed platelet aggregation inhibitors and 90.9 % 
were using statins. 38.6 % were using beta-blockers and 36.4 % used ACE inhibitors.15.9 % of 
participants were also using anti-diabetic medications (oral) and 4.5 % used insulin. Within the SF 
group 72.6 % were prescribed platelet aggregation inhibitors and 68.9 % were using statins. 37 % 
used ACE inhibitors and 34.8 % were using beta-blockers. 21.5 % of participants were also using 
anti-diabetic medications (oral) and 7.4 % used insulin. 
There was a significant difference between the FH and SF group in some of the medications used. 
The FH group had a higher use of platelet aggregation inhibitors (93.2%) (p= 0.003) and statins 
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(90.9%) (p= 0.003) when compared to the SF group. However, the SF group had a higher use of 
organic nitrates (13.6%) than the FH group (3.4%) (p<0.001). 
 
3.3.2 The physiological, functional and metabolic variables for all participants, the 
Fedhealth group (FH) and the Self funders group (SF) at entry into the programme (T1) 
The physiological variables for all participants, in both the FH group and the SF group is depicted in 
table 3.6. 
Table 3.6 Physiological variables for all participants, in the FH group and the SF group at entry 
into the programme (T1) 
  All (n = 179) FH (n = 44) SF (n = 135) 
  
Physiological variable Mean (SD) N Mean (SD) N Mean (SD) N P-Value 
Resting HR (b/min) 73 (13) 178 72 (12) 44 73 (13) 131  ns 
Resting BP: Systolic (mmHg) 126 (16) 178 127 (13) 44 126 (16) 131  ns 
Resting BP: Diastolic (mmHg) 78 (10) 178 77 (10) 44 78 (10) 131  ns 
Weight (kg) 87.9 (18.4) 178 85.4 (16.9) 44 88.7 (18.7) 131  ns 
Height (m) 1.7 (0.1) 177 1.7 (0.1) 44 1.7 (0.1) 131  ns 
BMI (kg/m
2
) 29.7 (5.8) 178 29.5 (5.7) 44 29.8(5.9) 132  ns 
Percentage Body Fat (%) 29.9 (6.1) 171 30.4 (7) 43 29.7 (5.8) 123  ns 
Sum Of Skin folds (mm) 73.6 (28.2) 172 74.4 (30.5) 43 73.4 (27.6) 126  ns 
Waist (cm) 100 (15) 177 99 (14) 44 101 (15) 129  ns 
Hip (cm) 105 (12) 177 105 (11) 44 105 (12) 129  ns 
Waist to Hip Ratio  1 (0.1) 178 0.9 (0.1) 44 1 (0.1) 133  ns 
FH = Fedhealth; SF = Self funders group 
N = number of participants; SD = standard deviation 
HR = heart rate; B/min = beats per minute; BP = blood pressure; mmHg =millimetres of mercury; kg = kilograms; 
m = meters; kg/m
2
 = kilogram per meter squared; % = percentage; Mm = millimetre; Cm = centimetre 
ns = no significant difference between the FH and SF groups 
 
 
Upon entry into the programme (T1), there were no significant differences in resting heart rate, resting 
systolic and diastolic blood pressure, weight, height, body mass index, body fat percentage, sum of 
skin folds, waist and hip circumference and waist to hip ratio between the FH group and SF groups. 
However, weight and waist circumference tended to be higher in the SF group compared to the FH 
group.  
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The functional variables for all participants, the FH group and the SF group is depicted in table 3.7. 
Table 3.7 The cardiovascular and functional capacity variables for all participants, the FH 
group and the SF group at entry into the programme (T1) 
  All (n = 179) FH (n = 44) SF (n = 135) P-Value 
Variables Mean (SD) N Mean (SD)  N Mean (SD)  N  ns 
Resting HR (b/min) 73 (13) 178 72 (12) 44 73 (13) 134  ns 
Resting BP: Systolic (mmHg) 126 (16) 178 127 (13) 44 126 (16) 134  ns 
Resting BP: Diastolic (mmHg) 78 (10) 178 77 (10) 44 78 (10) 134  ns 
Flexibility  (cm) 12  (12) 151 11 (9) 38 12 (12) 113  ns 
6 minute walk distance (m) 561 (154) 171 537 (125) 42 569 (162) 129  ns 
Max HR (b/min) 118 (21) 166 115 (19) 40 117 (23) 120  ns 
Rec HR 1min (b/min) 92 (16) 139 91 (14) 38 91 (17) 93  ns 
FH = Fedhealth; SF = Self funders group 
N = number of participants; SD = standard deviation 
HR = heart rate; B/min = beats per minute; BP = blood pressure; mmHg =millimetres of mercury; Cm = 
centimetre; m = meters; max = maximum heart rate during six minute walk test; Rec = recovery 
ns = no significant difference between the FH and SF groups 
 
 
There were no significant differences in the resting cardiovascular and functional capacity variables 
(resting heart rate, systolic and diastolic blood pressure, flexibility, six minute walk test distance, 
maximum heart rate achieved during the six minute walk test and recovery heart rate after the six 
minute walk test) between the FH group or SF group upon entry (T1) into the programme. However, 
the SF group’s six minute walk distance tended to be higher (569 m) than the FH group (537 m).  
 
The metabolic variables for all participants, the FH group and the SF group is depicted in table 3.8. 
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Table 3.8 The metabolic variables for all participants, the FH group and the SF group at entry 
into the programme (T1)  
  All (n = 179) FH (n = 44) SF (n = 135) P-Value 
Metabolic variable Mean (SD) N Mean (SD) N Mean (SD) N ns  
[Total cholesterol] 
(mmol/L) 
4.6 (1.2) 122 4.5 (1.1) 35 4.6 (1.2) 87 
 ns 
[HDL]  (mmol/L) 1.2 (0.7) 117 1.4 (0.9) 33 1.1 (0.5) 84  ns 
[LDL] (mmol/L) 2.9 (1) 117 2.8 (0.9) 34 2.9 (1.0) 83  ns 
[Triglyceride]  (mmol/L) 1.4 (0.6) 114 1.5 (0.8) 32 1.4 (1.0) 82  ns 
Fasting [glucose]  
(mmol/L) 
6.0 (1.4) 86 6.3 (1.9) 31 6.0 (1.5) 55 
 ns 
FH = Fedhealth; SF = Self funders group 
N = number of participants; SD = standard deviation 
Mmol/L = millimole per litre; HDL =high density lipoprotein; LDL; low density lipoprotein 
ns = no significant difference between the FH and SF groups 
There were no significant differences in the majority of metabolic variables (total cholesterol, HDL, 
LDL, triglycerides and fasting glucose) between the FH group and SF group upon entry (T1) into the 
programme.  
3.3.3 The effects of the 12 week intervention (CDRRRP) on the physiological, functional and metabolic 
variables in the FH group and SF group (T1 = entry, T2 = after 12 weeks of intervention) 
 
The physiological variables upon entry (T1) and at completion of the 12 weeks (36 sessions) (T2) in 
the FH group and SF group in depicted in table 3.9. 
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Table 3.9 The physiological variables upon entry (T1) and at completion of the 12 weeks (36 
sessions) (T2) in the FH group and SF group 
Variable  Group * T1** T2** P-value 
Weight (kg) FH (44) 85.4 (16.9) 84.8 (15.9)   ns 
 SF (131) 88.7 (18.7) 88.9 (18.8) ns 
BMI (kg/m2) FH (44) 29.5 (5.7) 29.2 (5.2) ns 
 SF (132) 29.8 (5.7) 29.7 (5.6) ns 
Percentage Body Fat (%) FH (42) 30.4 (7) 29 (6.8)  0.0008 
 SF (123) 29.7 (5.8) 28.1 (5.7) <0.0001 
Sum Of Skin folds (mm) FH (42) 74.4 (30.5) 66.9 (26.1)  <0.0001 
 SF (126) 73.5 (27.3) 65.4 (24.6)  <0.0001 
Waist (cm) FH (43) 99 (14) 96 (12)   0.0017 
 SF (129) 101 (15) 98 (14.3) <0.0001 
Hip (cm) FH (43) 104.5 (11) 103 (10)
 
0.0059 
 SF (129) 105 (12) 104 (12)
 
0.0001 
Waist to Hip Ratio  FH (43) 0.9 (0.1) 0.9 (0.1) ns 
 SF (133) 1 (0.1) 0.9 (0.1) 0.0001 
*= number of participants analyzed for each variable 
** = value represented as the mean with standard deviation in brackets 
FH = Fedhealth; SF = Self funders group; ns = no significance 
kg = kilograms; m = meters; kg/m
2
 = kilogram per meter squared; % = percentage; Mm = millimetre; Cm = 
centimetre 
 
The main aim of this study was to identify if a difference existed between the two groups of 
cardiovascular patients who completed the CDRRRP. As the results indicated no significant 
difference between the groups, further analysis was conducted to identify the differences seen from 
T1 to T2 for each group respectively. Tables 3.9 to 3.11 provide the data for this comparison. 
In the FH group, the mean weight decreased by 0.6 kg and mean body fat percentage decreased by 
1.4 % over the 12 weeks. Body fat percentage was significantly different at these two occasions (p= 
0.0008). At T2 there was also a significant difference in the mean sum of skin folds, whereby the 
mean sum of skin folds decreased by 7.5 mm. The mean body mass index at 12 weeks was 29.2 
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kg/m
2
, which was not significantly different from the T1. The mean waist-to-hip ratio remained the 
same at 0.9 cm. All physiological variables, weight and body mass index were significantly different at 
12 weeks. 
Over 12 weeks, the mean weight of the SF at T2 was not significantly different from T1, but the mean 
body fat percentage reduced by 1.6 %, this was significantly different (p<0.0001).  There was a 
significant difference in the mean sum of skin folds, which decreased   from 73.5 mm  to 65.4 mm at 
12 weeks (p-value: < 0.0001). The mean body mass index at 12 weeks was 29.7 kg/m
2
, which did not 
differ significantly from 29.8 kg/m
2
. The mean waist-to-hip ratio differed significantly from 1.0 to 0.9 (p 
< 0.0001). All the physiological variables, except weight and body mass index at 12 weeks were 
significantly different and the mean differences were decreased from baseline (paired t-test, all p < 
0.001).  
There was no statistically significant difference between the FH and SF groups in the outcomes 
measured at baseline and at 12 weeks. 
The functional variables upon entry (T1) and at completion of the 12 weeks (36 sessions) (T2) in the 
FH group and SF group in depicted in table 3.10. 
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Table 3.10 The functional variables upon entry (T1) and at completion of the 12 weeks (36 
sessions) (T2) in the FH group and SF group 
Functional Variable Group * T1** T2** P-value 
Resting HR (b/min) 
FH (42) 72 (12) 69 (9)  ns 
SF (131) 73 (13) 70 (12)  0.0004 
Resting BP: Systolic (mmHg) 
FH (42) 127 (13) 122 (13)  0.0083 
SF (131) 126 (16) 120 (13)  <0.0001 
Resting BP: Diastolic (mmHg) 
FH (42) 77 (10) 72 (10)  0.0007 
SF (131) 78 (10) 73 (9)  <0.0001 
Flexibility (cm) 
FH (36) 11 (9) 16 (8)  <0.0001 
SF (109) 12 (12) 16 (11)  <0.0001 
6 minute walk Distance (m) 
FH (41) 537 (125) 617 (134)  <0.0001 
SF (123) 569 (162)  668 (208)  <0.0001 
Max HR (b/min) 
FH (38) 115 (19) 125 (19)  0.0049 
SF (115) 119 (23) 125 (24)  0.0001 
Rec HR 1min (b/min) 
FH (35) 91 (14) 91 (15) ns 
SF (87) 91 (17) 96 (19)  ns 
*= number of participants analyzed for each variable 
** = value represented as the mean with standard deviation in brackets 
FH = Fedhealth; SF = Self funders group 
N = number of participants; SD = standard deviation 
HR = heart rate; B/min = beats per minute; BP = blood pressure; mmHg =millimetres of mercury; Cm = 
centimetre; m = meters; Rec = recovery 
 
The FH groups mean distance walked at 12 weeks was 617 m, this was significantly different from the 
baseline mean of 537 m (p<0.0001). The mean difference reflected an improvement of 80 m or 12 %. 
There was a significant difference in the mean systolic blood pressure, at 12 weeks, the mean was 
122 mmHg, which was a reduction from 127 mmHg (p: 0.0083). The mean diastolic blood pressure at 
12 weeks was 72 mmHg, reflecting a reduction from 77 mmHg, this was also significantly different 
from the T1 (p: 0.0007). The mean resting heart rate at 12 weeks was 69 b/min, which decreased 
from 72 b/min. This however was not significantly different. 
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The SF groups mean distance walked at 12 weeks was 668 m and was also significantly different 
from the baseline mean of 569 m (p<0.0001).  The SF mean difference also reflected an improvement 
of 99 m or 14 % at 12 weeks.  The mean diastolic blood pressure at 12 weeks was 73 mmHg, this 
also differed significantly from the T1 (p < 0.0001). The mean resting heart rate at 12 weeks was 70 
b/min, which was significantly different from the T1 (p: 0.0004).  
The mean flexibility of the FH and SF group at 12 weeks was 16 cm, both were significantly different 
(p < 0.0001) from their starting values (T1). Overall, there was no significant difference between the 
responses of these two groups for these measures of functional capacity from baseline to 12 weeks. 
All the functional variables, except resting heart rate and recovery heart rate for the FH group at 12 
weeks were significantly different and the mean differences were decreased from baseline. 
There was no statistically significant difference between the FH and SF groups in the outcomes 
measured at baseline and at 12 weeks. 
The metabolic variables upon entry (T1) and at completion of the 12 weeks (36 sessions) (T2) in the 
FH group and SF group in depicted in table 3.11. 
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Table 3.11 The metabolic variables upon entry (T1) and at completion of the 12 weeks (36 
sessions) (T2) in the FH group and SF group 
Metabolic Variable Group * T1** T2** P-value 
Total [cholesterol] (mmol/L) 
FH (23) 4.5 (1.1) 4.3 (1.0)
 
 ns 
SF (48) 4.6 (1.2) 4.2 (1.0)  0.0035 
[HDL]  (mmol/L) 
FH (23) 1.4 (0.9) 1.1 (0.3)  ns 
SF(48) 1.1 (0.5) 1.1 (0.4) ns 
[LDL] (mmol/L) 
FH(23) 2.8 (0.9) 2.6 (0.7)  ns 
SF (47) 2.9 (1.0) 2.6 (0.8)  0.0005 
[Triglyceride]  (mmol/L) 
FH (21) 1.5 (0.8) 1.2 (0.5)  0.047 
SF (47) 1.4 (0.6) 1.4 (0.9)  ns 
Fasting [glucose] (mmol/L) 
FH (19) 6.3 (1.9) 6.1 (1.4)  ns 
SF (20) 6.0 (1.5) 5.9 (0.9)  ns 
*= number of participants analyzed for each variable 
** = value represented as the mean with standard deviation in brackets 
FH = Fedhealth; SF = Self funders group 
N = number of participants; SD = standard deviation 
mmol/L = millimole per litre; HDL =high density lipoprotein; LDL = low density lipoprotein 
 
In the FH group, there was no significant difference in total cholesterol which decreased from 4.5 
mmol/L to 4.3 mmol/L, LDL also reflected no significant difference, with the mean decreasing from 2.8 
mmol/L to 2.6 mmol/L, there was no significant difference in HDL , which also decreased from 1.4 
mmol/L to 1.1 mmol/L. However, triglycerides did significantly differ and the mean value decreased 
from 1.5 mmol/L to 1.2 mmol/L (p= 0.047). Fasting glucose showed no significant difference but the 
mean value decreased from 6.3 mmol/L to 6.1 mmol/L. Total cholesterol in the SF group significantly 
differed from T1 to T2, the mean value decreased from 4.6 mmol/L to 4.2 mmol/L (p= 0.0035), LDL 
significantly differed and the mean value decreased from 2.9 mmol/L to 2.6 mmol/L (p= 0.0005), HDL 
remained the same at 1.1 mmol/L, triglycerides also remained the same 1.4 mmol/L and fasting 
glucose showed no significant difference. There was no significant difference between the SF and FH 
groups in the metabolic variables measured at baseline and at 12 weeks. 
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3.3.4 The effects of the 12 week intervention (CDRRRP) on the physiological, 
functional and metabolic variables in all participants 
The analysis of the 12-week intervention programme on the physiological, functional and metabolic 
variables in the FH and SF groups showed that there were no significant differences between the two 
groups (section 3.3.3) Therefore, the effect of the 12 week intervention programme on the combined 
participants (n=179) was analyzed. This analysis is important as it will depict the overall benefits of 
the intervention on the physiological, functional and metabolic variables in patients with 
cardiovascular disease.  
The physiological variables upon entry (T1) and at completion of the 12 weeks (36 sessions) (T2) for 
all participants is depicted in table 3.12. 
Table 3.12 The physiological variables upon entry (T1) and at completion of the 12 weeks (36 
sessions) (T2) for all participants 
Physiological variable N T1* T2* P-Value 
Weight (kg) 175 87.9 (18.4) 87.9 (18.1) ns 
Height (m) 175 1.7 (0.1) 1.7 (0.1) ns 
BMI (kg/m
2
) 
176 29.7 (5.8) 29.6 (5.5) ns 
Percentage body fat (%) 165 29.9 (6.1) 28.4 (6) < 0.0001 
Sum of skin folds (mm) 168 73.6 (28.2) 65.8 (24.9) <0.0001 
Waist (cm) 172 100 (15) 98 (14) <0.0001 
Hip (cm) 172 105 (12) 104 (11) <0.0001 
Waist to hip ratio  176 1 (0.1) 0.9 (0.1) <0.0001 
*= mean value with standard deviation 
ns = no significance 
T1 = Assessment at baseline; T2 = assessment at completion of 12 weeks (36 sessions) intervention; 
kg = kilograms; m = meters; kg/m
2
 = kilogram per meter squared; % = percentage; Mm = millimetre; Cm 
= centimetre 
P value = significant differences between T 1 and T2 
 
In all participants, mean weight did not change over 12 weeks but percentage body fat significantly 
differed from baseline by 1.4 % (p < 0.0001). The mean sum of skin folds difference decreased from 
73.6 mm at baseline to 65.8 mm at 12 weeks (p < 0.0001).  The mean body mass index at 12 weeks 
was 29.6 kg/m
2
, which did not change significantly from baseline (29.7 kg/m
2
). However, mean waist-
to-hip ratio was significantly different, the mean improved from 1.0 cm to 0.9 cm (p<0.0001). 
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Therefore, there was a significant improvement body fat percentage by 1.4 %, sum of skin folds by 10 
%, waist circumference, hip circumference and waist-hip ratio in the group of all participants. 
 
The functional variables upon entry (T1) and at completion of the 12 weeks (36 sessions) (T2) for all 
participants is depicted in table 3.13. 
Table 3.13 The functional variables upon entry (T1) and at completion of the 12 weeks (36 
sessions) (T2) for all participants 
Functional variable N T1* T2* P-Value 
Resting HR (b/min) 
173 73 (13) 70 (11) 0.0001 
Resting BP: Systolic (mmHg) 
173 126 (16) 120 (13) <0.0001 
Resting BP: Diastolic (mmHg)  
173 78 (10) 72 (9) <0.0001 
Flexibility (cm) 
145 12 (12) 16 (11) <0.0001 
6 minute walk Distance (m) 
164 561 (154) 655 (193) <0.0001 
Max HR (b/min) 
153 118 (21) 125 (23) <0.0001 
Rec HR 1min (b/min) 
122 97 (16) 95 (18) ns 
*= mean value with standard deviation 
T1 = assessment at baseline; T2 = assessment at completion of 12 weeks (36 sessions) intervention; N 
= number of participants; SD = standard deviation; ns = no significance 
HR = heart rate; B/min = beats per minute; BP = blood pressure; mmHg =millimetres of mercury; Cm = 
centimetre; m = meters; max = maximum heart rate achieved during six minute walk test; Rec = 
recovery heart rate after six minute walk test 
P value = significant differences between T 1 and T2 
 
 
The mean systolic blood pressure showed a decrease at 12 weeks from what 126 mmHg o 120 
mmHg, this was significantly different (p < 0.0001), and the mean diastolic blood pressure also 
decreased at 12 weeks from 78 mmHg to 72 mmHg, and was also significantly different ( p . < 
0.0001). The mean resting heart rate at 12 weeks was 70 b/min, which also showed a significant 
difference from 73 b/min at baseline (p: 0.0001). The mean 6 minute walk test distance was 
significantly different (p < 0.0001) at 12 weeks. The mean 6 minute walk test improved to from 561 m 
at baseline 655 m (an improvement of 14 %). The mean flexibility at 12 weeks was significantly 
different at 16 cm, improving from 12 cm at baseline (25 % improvement; p < 0.0001). Overall, there 
was a significant improvement in the functional variables at 12 weeks (36 sessions) for all 
participants.  
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The metabolic variables upon entry (T1) and at completion of the 12 weeks (36 sessions) (T2) for all 
participants is depicted in table 3.14. 
Table 3.14 The metabolic variables upon entry (T1) and at completion of the 12 weeks (36 
sessions) (T2) for all participants 
Metabolic variable N T1* T2* P-Value 
Total [cholesterol] (mmol/L) 71 4.6 (1.2) 4.2 (1.0)  0.0015 
[HDL] (mmol/L) 71 1.2 (0.7) 1.1 (0.4)  ns 
[LDL] (mmol/L) 70 2.9 (1.0) 2.6 (0.8)  0.0001 
[Triglyceride] (mmol/L) 68 1.4 (0.6) 1.3 (0.8)  ns 
Fasting [glucose] (mmol/L) 39 6 (1.4) 6 (1.5)  ns 
*= mean value with standard deviation 
T1 = assessment at baseline; T2 = assessment at completion of 12 weeks (36 sessions) intervention; N 
= number of participants; SD = standard deviation; ns = no significance 
mmol/L = millimole per litre; HDL =high density lipoprotein; LDL = low density lipoprotein 
P value = significant differences between T 1 and T2 
 
 
There was a significant difference in total fasting cholesterol concentration, the mean difference 
decreased by 0.4 mmol/L (p= 0.0015). LDL concentration was also significantly different, the mean 
decreased by 0.3 mmol/L (p: 0.0001). However, there were no significant changes in HDL, 
triglycerides and fasting glucose concentrations after 12 weeks. Overall, there was a significant 
improvement in some metabolic variables at 12 weeks (36 sessions).  
 
3.3.4 Patients that withdrew from the programme 
The risk factor profile for all participants that withdrew from the programme and did not have a re-
assessment is depicted in table 3.15. 
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Table 3.15 Risk factor profile for participants that withdrew from the programme. 
Total group of participants that 
withdrew  
T1 (n=25) 
Risk factor Count 
Gender (Males) 19 (76) 
Hypertension 15 (60) 
Hypercholesterolemia 17 (68) 
Diabetes 8 (32) 
Family history 17 (68) 
Overweight 17 (68) 
Sedentary 19 (76) 
          N = number of participants 
       Value represented as the number of participants with the percentage in brackets 
 
Within the total group 11.9 % (25/209) of patients did not complete the programme.76 % were male. 
16 % (4/25) were from the FH group and 84 % (21/25) from the SF group. 60 % had high blood 
pressure, 68 % had high cholesterol, 32 % had diabetes, 68 % had a family history of cardiovascular 
disease, 76 % were sedentary and 28 % were smokers. 
 
The physiological, functional and metabolic variables upon entry (T1) for all participants that withdrew 
from the programme are depicted in table 3.16. 
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Table 3.16 The physiological, functional and metabolic variables for all participants who 
withdrew from the programme (T1) 
Total group that withdrew 
Variable Mean (SD) N 
Age (years) 58 (11) 25 
Total cholesterol (mmol/L) 5.3 (1.1) 9 
HDL (mmol/L) 0.9 (0.1) 9 
LDL (mmol/L) 3.1 (0.9) 9 
Triglycerides (mmol/L) 2.8 (2.3) 9 
Fasting Glucose (mmol/L) 7.0 (3.3) 8 
Resting HR (b/min) 77 (11) 24 
Resting BP: Systolic (mmHg) 120 (14) 24 
Resting BP: Diastolic (mmHg) 75 (11) 24 
Weight (kg) 89.6 (16.6) 25 
Height (m) 1.7 (0.1) 25 
BMI (kg/m
2
) 29.7 (4.9) 25 
Percentage Body Fat (%) 31.1 (6.3) 24 
Sum of skin folds (mm) 79.3 (30.3) 25 
Waist (cm) 99 (13) 25 
Hip (cm) 106 (11) 25 
Waist to hip ratio (cm) 0.9 (0.1) 25 
Flexibility (cm) 11 (8) 19 
Distance (m) 500 (158) 21 
Max HR (b/min) 114 (24) 21 
Rec HR 1min (b/min) 90 (15) 19 
SD= Standard deviation; N = number of participants; HDL = high density lipoprotein; LDL = low 
density lipoprotein; Mmol = millimole; HR = heart rate; b/min = beats per minute; BP = blood 
pressure; mmHg = millimetres of mercury; kg = kilogram; m = meters; kg/m
2
= kilogram per 
meter squared; % = percentage; mm = millimetres; cm = centimetres; Rec = recovery 
 
3.4. Discussion 
The main aim of this study was to determine if there was a difference in physiological, functional and 
metabolic variables, following a 12 week lifestyle intervention program, between a group of patients 
with chronic disease who were referred and funded by their medical insurer (FH group) compared to a 
group of patients with chronic disease who were self referred and funded (SF group). The main 
finding from this study was that the 12-week comprehensive lifestyle intervention significantly 
improved the majority of the physiological, functional and metabolic variables in both groups. In 
general, there were no significant differences in the outcomes measured between a medical insurers 
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funded group and the self funded group. Furthermore, dropout rates between the two groups were 
also similar, (Fedhealth group = 8 % and Self-funders = 13 %) indicating that there was very little 
difference in adherence and readiness to make changes to lifestyle behaviours between the two 
groups. This dropout rate was less than that reported in a study by Worcester et al 
103
 investigating 
cardiovascular rehabilitation non-attendance. In that study, there was a 24 % drop out rate amongst 
the participants
103
. 
 
To our knowledge, there has been no other published study where two groups of patients entering a 
chronic disease programme from different referral and funding sources (such as the ones used in this 
study) were compared. Therefore, we cannot compare our results to other study results. These data 
do however suggest that the compliance of the patients with chronic disease in our lifestyle 
intervention program was similar irrespective whether they have been referred and fully funded or 
have taken the initiative to self-fund the intervention programme. This is an important finding because 
it could be suggested that there are differences in motivation, adherence, completion of the 
programme and outcomes achieved, in self-funded compared with externally funded patients.  A 
possible explanation for this finding is that all the patients did experience a significant event affecting 
their health status, and this was sufficient to prompt them to enrol and complete the programme. This 
life-changing event could be the reinforcing factor that motivates patients sufficiently to sustain 
lifestyle changes and attempt to improve their health so that the risk of future events is reduced. 
 
Therefore, as previously mentioned, the effects of the 12-week lifestyle intervention was analysed for 
the entire group, because no differences were observed between the two groups. These results are 
important because they determine if the 12-week intervention program was effective in improving 
physiological, functional and metabolic variables in patients with chronic cardiovascular disease and 
co-morbidities.  
 
Thus, the second major finding of this study was that we observed clinically significant improvements 
in most of the outcome variables (physiological, functional, and metabolic) within the total group of 
participants who completed the 12-week lifestyle intervention program.  These results are similar to 
those documented for other lifestyle intervention programmes aimed at reducing chronic disease risk 
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factors. Collectively these data suggest that a multi-component lifestyle approach is an effective 
intervention for reducing the risk factors for chronic disease 
51;52;56;61;64;70;93;94;104;105
. Our study is 
however unique in that 1) the beneficial effects were observed in a short period (12 weeks) compared 
with other similar studies such as the Lifestyle 180 programme (30 week intervention)
55
, 2) it is 
medically supervised, and 3) it is multidisciplinary in nature.  
 
More specifically we showed that the improvements in all the physiological variables in our study were 
similar to those reported in the Lifestyle 180 programme 
56
, with the exception of body weight and 
body mass index (BMI). The Lifestyle 180 programme reported greater improvements in body weight 
and BMI at 30 weeks compared to our intervention at 12 weeks. The most likely explanation for this 
difference in response is the longer period of the Lifestyle 180 program 
56
.  
Not only were there changes in body weight and percentage body fat, but also abdominal obesity 
decreased, reflected by the mean difference decrease in waist circumference. This is of clinical 
importance, due to the association between abdominal obesity and type II diabetes mellitus, which is 
also a risk factor for cardiovascular disease. However, there was no difference observed in the waist 
to hip ratio. A possible explanation for this finding could be the observed decrease in weight, waist 
and hip circumference. Greater improvements in these variables were seen in the SLIM study 
106
 
whereby the authors reported a mean difference of 3.5 cm in waist circumference, however, this was 
recorded at one year post intervention. Our study showed a mean difference decrease of 2 cm at 12 
weeks.  
 
Perhaps the single most important risk factor for cardiovascular disease is hypertension 
2;89;92;107;108
. 
Indeed, a large number of studies have examined the effects of exercise training on various indices of 
cardiovascular function. The single most replicable effect of aerobic training on cardiac function is a 
decreased resting heart rate 
109
. 
The physical conditioning achieved by regular exercise decreases heart rate and blood pressure at 
rest 
42
and  reduces workload on the heart, helping to alleviate cardiovascular disease related 
symptoms including angina 
42
. A study by Maiorana et al 
110
 showed a similar mean decrease in 
resting heart rate of 3 b/min and mean systolic and diastolic blood pressure of also 3 mmHg. These 
findings were shown after 8 weeks of an exercise intervention. The TOMHS
50
 study showed a mean 
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difference decrease in systolic blood pressure of 10 mmHg and mean difference decrease in diastolic 
blood pressure of 8 mmHg. These variables were measured at one year post intervention. The 
Lifestyle 180 programme 
55
 also showed similar results in their resting heart rate (mean difference 
decrease of 7 b/min). Whilst it is important to note that the patients in our study were not clinically 
hypertensive or were well controlled on medication yet there was still an effect on the measured 
cardiovascular parameters. Indeed, the results of the studies mentioned above, are consistent with 
our study which showed a mean difference reduction of 3 b/min in resting heart rate and a mean 
difference decrease of 6 mmHg in both systolic and diastolic blood pressure at 12 weeks post 
intervention. The main difference between these studies is the period of the intervention, which will 
affect the outcome of these variables being measured. Future studies conducted on this present 
cohort will address the longer period of intervention.   
Therefore, our intervention was effective in improving the resting heart rate and resting blood 
pressure (systolic and diastolic) in patients with chronic disease. The results from our study and 
supporting studies provide evidence that a holistic lifestyle intervention program that combines 
exercise, diet and management of other risk factors result in reduced risk factors for chronic disease 
111
. 
 
The third important finding from the present study was that, we showed that the intervention resulted 
in significant improvements in the functional variables measured. Of significance was the 
improvement seen in the 6-minute walk test.  This test is commonly used in clinical settings and 
chronic diseases rehabilitation programmes such as the CDRRRP to measure the impact of multiple 
co-morbidities (including cardiovascular disease, respiratory disease, diabetes, arthritis and 
psychological diseases) on exercise capacity and endurance 
16
.The 6-minute walk test has been 
shown to be a reliable measurement of functional capacity in patients with chronic disease. 
99
. It has 
been shown that an improvement of more than 70 m walked or 12 % is clinically important to patients 
16;112
. Even the slightest difference in six minute walk test distance can be associated with a 
noticeable difference in patients personal assessment of their walking ability, thus indicating 
improvement in their functional capability 
113
. 
 This is relevant because the average improvement in the 6-minute walk test in our study was 94 m 
(Table 3.13) which equates to a 14 % improvement. Similar improvements in 6-minute walk test 
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results were also documented previously in patients with heart failure after 12 weeks of exercise 
prescription
105
.   
 
The sit-and-reach test used in our study estimates the flexibility of the hamstrings and lower back, 
which could be potential precursors for lower back injuries and pain 
42
. Our intervention showed a 
mean difference increase of 4cm, showing a 25 % improvement.  This change is clinically important to 
patients with chronic disease in possibly helping to prevent further incidences of lower back injury and 
pain.  In comparing our results to the other similar studies, none used the sit and reach test (or any 
other flexibility test) as a functional measure, therefore no comparison can be made. Therefore in 
summary, our intervention was effective in improving the functional capacity of patients with chronic 
disease with respect to these measured variables. 
 
The fourth finding from this study was that we documented a small but significant improvement in total 
cholesterol and LDL concentrations in the overall group as well as in the two sub-groups. In general 
however, upon entry onto the CDRRRP, the lipid profiles were well managed and mostly controlled in 
our patient population through the use of medications (table 3.5). Indeed, over 70 % of all patients in 
our cohort were using cholesterol-lowering medications. Yet, in our study we documented additional 
small yet statistically significant improvements in most measured metabolic variables, and this 
suggests that this additive impact might be an effect of the programme. The reductions observed in 
triglycerides, total cholesterol, and LDL cholesterol are consistent with other similar chronic disease 
programs
50, 51, 55, 63, 93, 94, 105
. 
The Lifestyle 180 programme
55
 reported a mean difference decrease of 0.7 mmol/L in total fasting 
cholesterol, 0.1 mmol/L in HDL, 0.5 mmol/L in LDL and 0.4 mmol/L in triglyceride concentrations at 30 
weeks. In the present study we documented similar changes but over a shorter intervention period of 
12 weeks. Total fasting cholesterol showed a mean difference decrease of 0.4 mmol/L, 0.1 mmol/L in 
HDL, 0.3 mmol/L in LDL and 0.1 mmol/L in triglyceride concentration. Our study did not however 
show a change in fasting glucose concentrations. Indeed, the mean fasting glucose concentrations in 
the patients in this study indicate that control could be improved. A possible explanation for this 
finding could be the relatively small change seen in weight reduction which is known to be associated 
with improved insulin function as well as the short duration of the intervention compared to other 
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studies over a longer period of time 
106
. 
 
Study limitations 
This study has several limitations, which include the following: 
 In our study we did not have a control group with no intervention. Our study design was 
started as a pilot study for the Fedhealth group and data were analysed retrospectively. 
Furthermore, as lifestyle intervention is firstly line therapy for patients with chronic disease, 
there are ethical considerations in withholding this form of advice or intervention form patients 
with chronic disease. 
 As this was a retrospective study over a 5-year period, a limitation is missing data. Some 
patients had incomplete records, which contributed towards missing variables of some 
measurements. In addition, there were 25 patients who did not complete the programme; 
therefore no re-assessment data was available on these patients.Some of the missing data 
relates to repeat blood testing. This may be due to the additional financial costs of repeat 
blood testing in the patients from the self -funded group. It is well documented that one of the 
barriers to exercise and lifestyle changes, is financial because there are cost implications in 
maintaining changes that include medication adherence, continued follow-up consultations 
with medical staff, and repeat clinical examinations and procedures 
67
.  
 The location of the programme was restricted to one centre, therefore geographical limitations 
prevented all patients from the main funder (Fedhealth) to be included in the study – this 
could have resulted in some selection bias and is presently being addressed by presenting 
this programme across a wider National representation.  
 Although this was a relatively large cohort, more detailed analysis of multiple factors and sub-
groups (e.g. different profiles of co-morbidities) was not possible due to small sample sizes of 
sub-groups.  
 In this study we did not measure all aspects of fitness, such as muscle strength testing. This 
will be addressed in future planned studies of patients on this programme.  
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
 
 
75 
 A longer observation period would have provided a better opportunity for further favourable 
changes to occur. A six-month study observation period is presently being analysed in a 
further study on this programme.  
In summary, the findings from our pilot study provide a clear indication that the CDRRR program is 
successful in reducing risk factors for chronic disease, improving outcome measurements amongst 
participants regardless of the referral and funding strategy used into the programme, reducing 
physical inactivity as a risk factor for chronic disease and improving functional capacity of the patients 
to a level that will permit better performance of daily tasks, activities and overall quality of life. 
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Chapter 4 
Summary and conclusion 
Summary 
The global burden of chronic disease has highlighted the need for more holistic, comprehensive 
interventions for the management and prevention of the progression of chronic disease. Due to the 
high prevalence of patients with more than one chronic disease and co-morbidities, these 
interventions have shifted from disease specific treatments to patient centred approaches. The key 
components of chronic disease rehabilitation should include individualised exercise prescription and 
training, education, dietary and nutrition interventions, psychosocial support and strategies to modify 
other risk factors. One of the biggest challenges individuals with chronic disease face is the 
implementation of these new healthy behaviours. The focus of this dissertation was to determine the 
effectiveness of a multi disciplinary chronic disease programme on outcomes in patients with chronic 
disease. In particular, the difference in outcomes between the two groups of patients who were 
referred and funded with different models.  
 
Whilst previous studies have shown the benefits of a multidisciplinary lifestyle intervention programme 
on chronic disease patients’ health and risk factor status, 
2;61;66
 there has not, to the best of our 
knowledge, been any research comparing two groups from different referral and funding strategies 
into a medically supervised chronic disease rehabilitation programme. 
 
The data from this study revealed the effectiveness of the CDRRR programme on most outcomes for 
patients who completed the programme. Indeed patients enrolled on this programme showed 
improvements in percentage of body fat; sum of skin folds, waist and hip circumference, waist to hip 
ratio; resting heart rate, systolic and diastolic blood pressure, flexibility, six minute walk test distance, 
maximum heart rate achieved and recovery heart rate, total fasting cholesterol and low density 
lipoprotein. The results of the study also showed that no difference exists in outcomes achieved 
between the two groups with different referral and funding strategies for the programme.  
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Conclusion 
Chronic diseases continue to drive the healthcare costs even though they are largely preventable. 
Whilst specific treatments and medications continue to target the established pathology of the 
disease-related condition, it is important that lifestyle factors are addressed in a safe and patient-
centred  manner Multi-component lifestyle interventions such as The Chronic Disease Risk Reduction 
and Reversal Programme described in this study are aimed at inducing  physiological adaptations and 
improvement of risk factor awareness, hopefully leading to behaviour modifications that support long-
term healthier lifestyle choices.  
 
The findings of the present study indicate that no difference in measured outcome exists between 
patients who are proactively referred and funded compared to those who are self referred and funded 
through a lifestyle intervention programme. This implies that there is no difference between 
compliance, adherence and adaptation of these patients to modifying their lifestyle behaviours. It is 
therefore evident that patients with chronic disease can improve their disease related risk factors by 
engaging and completing a multi-component lifestyle intervention consisting of physical activity, 
educational modules, dietary and stress management. All physiological, metabolic and functional 
measures in this study were improved at 12 weeks of intervention.  
 
In conclusion, the multi disciplinary chronic disease programme described is effective in improving the 
health status of patients with established chronic disease.  The referral strategy of patients into this 
programme also proved no difference to achieved, outcomes and patients who engage and complete 
the programme demonstrate the first step in taking control and managing their health. These findings 
could be used to encourage medical insurers to support and provide the financial support necessary 
to improve the overall long term cost of chronic disease. 
. 
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